FORM 10-K

                     SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C. 20549 

           	(Mark One)	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF 
	                    X 	THE SECURITIES EXCHANGE ACT OF 1934 

                     For the fiscal year ended May 31, 1997

                                  OR

           			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF 
                     THE SECURITIES EXCHANGE ACT OF 1934

              For the transition period from                  to 

                       Commission file number 0-14820

                             IMMUCOR, INC.
            (Exact name of registrant as specified in its charter)

               	Georgia                 	          22-2408354
 (State or other jurisdiction of        (I.R.S. Employer Identification No.)
 incorporation of organization)

     	3130 GATEWAY DRIVE,	30091
	          P.O. BOX 5625                            30091 (Zip Code)
        	Norcross, Georgia
	(Address of principal executive offices)

     Registrant's telephone number, including area code, is (770) 441-2051

         Securities registered pursuant to Section 12(b) of the Act: 

                                  NONE

         Securities registered pursuant to Section 12(g) of the Act: 

                      COMMON STOCK, $.10 PAR VALUE
                           (Title of Class)

                      COMMON STOCK PURCHASE RIGHTS
                           (Title of Class)

	Indicate by check mark whether the registrant (1) has filed all reports 
required to be filed by Section 13 or 15(d) of the Securities Exchange Act 
of 1934 during the preceding 12 months (or for such shorter period that the 
Registrant was required to file such reports), and (2) has been subject to  
such filing requirements for the past 90 days.
                             YES 	X		NO 		
	Indicate by a check mark if disclosure of delinquent filers pursuant to Item 
405 of Regulation S-K is not contained herein, and will not be contained, to 
the best ofregistrant's knowledge, in definitive proxy or information 
statements incorporated by reference in Part III of this Form 10-K or any 
amendment to  this Form 10-K.	[    X   ]

	As of August 15 1997, the aggregate market value of the voting stock held by 
non-affiliates of the registrant was $66,350,624.  

	As of August 15 1997, there were 8,078,737 shares of common stock
outstanding.

                              PART I
 Item 1.-Business

     	Founded in 1982, Immucor, Inc., a Georgia corporation ("Immucor" or the
 "Company"), develops, manufactures and sells a complete line of reagents and
 systems used primarily by hospitals, clinical laboratories and blood banks
 in a number of tests performed to detect and identify certain properties of
 the cell and serum components of human blood prior to blood transfusion.

     	The Company is also developing two automated blood bank instruments to
 perform blood compatibility tests currently done manually by blood bank
 technologists.  One instrument is designed for patient testing in hospital 
 transfusion laboratories while the second instrument is designed for donor
 testing in blood donor centers.  Both instruments utilize the Company's
 proprietary Capture (registered trademark) product technology. 

     	On December 11, 1996, Immucor acquired all of the common stock of
 Dominion Biologicals Limited ("Dominion").  Located in Dartmouth, Nova Scotia,
 Canada, Dominion develops, manufactures and sells products similar to those
 produced by the Company.  In addition, Dominion produces blood testing
 reagents from genetically engineered and other biological source materials.
 See Products Under Development - Monoclonal Antibodies.

      In January 1997, Immucor signed an exclusive distribution agreement with
 Biometric Imaging, Inc. to market their novel, proprietary cellular analysis
 system known as the IMAGN (registerd trademark) 2000.  This system provides 
 rapid, precise and  easy-to-perform cell test procedures to monitor disease 
 progression and the efficacy of therapy for patients undergoing transfusion 
 therapy and for HIV+ patient monitoring.

 Industry

     	Immucor is part of the immunohematology industry, which generally seeks to
 prevent or cure certain diseases or conditions through the transfusion of
 blood and blood components.  In the U.S. the Food and Drug Administration 
(the "FDA") treats human blood as a drug and as a biological product, and it
 treats the transfusion of blood as the administration of a drug and of a
 biological product.  The FDA regulates all phases of the immunohematology
 industry, including donor selection and the collection, classification,
 storage, handling and transfusion of blood and blood components.  The FDA
 requires all facilities that manufacture products used for any of those
 purposes, and the products themselves, to be registered or licensed by the
 FDA.  See Regulation of Business.

     	The principal components of blood are plasma (the fluid portion) and
 cells. Blood also contains antibodies and  antigens.  Antibodies are proteins
 that are produced in response to the introduction of foreign substances
 (antigens). Antigens are substances that stimulate the production of
 antibodies.  Red blood cells, which transport oxygen from the lungs to other
 parts of the body, and return the carbon dioxide to the lungs, are categorized
 by four blood groups (A, B, AB and O) and two blood types (Rh positive and Rh
 negative), based on the presence or absence of certain antigens on the surface
 of the cells.  It is crucial that the health care provider correctly identify
 the antibodies and antigens present in patient and donor blood.  For example,
 if a donor's red blood cells contain antigens that could react with the
 corresponding antibody in the patient's plasma, the transfusion of the red
 blood cells may result in the potentially life threatening destruction of
 the red blood cells.

     	Because of the critical importance of matching patient and donor blood,
 compatibility testing procedures are generally performed manually by highly
 educated technologists in hospitals, blood banks and laboratories.  At
 present, with few exceptions, these tests are performed using procedures
 which the Company believes can be significantly improved using its solid
 phase testing system to automate the testing procedures.  See Products -
 Solid Phase Technology and Products Under Development.

     	The Company believes that the worldwide market for traditional blood bank
 reagents is approximately $250 million, and that this market is relatively
 mature given current technology.  However, because the industry is labor-
 intensive, the introduction of labor-saving products may provide additional
 growth in the market.  The Company believes that its solid phase blood testing
 system improves test results and reduces the time necessary to perform certain 
 test procedures, thereby offering a cost-effective alternative for its
 customers.  See Products - Solid Phase Technology and Products Under
 Development.


 Products

     	Most of Immucor's current reagent products are used in tests performed
 prior to blood transfusions to determine the blood group and type of patients'
 and donors' blood, in the detection and identification of blood group
 antibodies, in platelet antibody detection, in paternity testing and in
 prenatal care. The FDA requires the accurate testing of blood and blood
 components prior to transfusions using only FDA licensed reagents such as
 those manufactured and sold by the Company. 

     	The following table sets forth the products sold by the Company, most of
 which are manufactured by the Company. 
 Product Group                   Principal Use

 ABO Blood Grouping              Detect and identify ABO antigens on red blood
                                 cells in order to classify a specimen's
                                 blood group as either A, B, AB or O.

 Rh Blood Typing                 Detect Rh antigens in order to classify a
                                 specimen as either Rh positive or Rh
                                 negative, and to detect other Rh-hr antigens.

 Anti-human Globulin             Used with other products for routine
  Serums (Coombs Serum)          crossmatching, and antibody detection and
                                 identification; allows a reaction to occur by
                                 bridging between antibodies that by themselves 
                                 could not cause a reaction.

 Reagent Red Blood Cells         Detect and identify antibodies in patient or
                                 donor blood, confirm ABO blood grouping
                                 results and validate the performance of
                                 anti-human serum in the test system.

 Rare Serums                     Detect the presence or absence of rare
                                 antigens.

 Antibody Potentiators           Increase the sensitivity of antigen-antibody
                                 tests.

 Quality Control System          Daily evaluation of the reactivity of routine
                                 blood testing reagents.

 Monoclonal (Hybridoma)   
  Antibody-based Reagents        Detect and identify ABO and other antigens on
                                 red blood cells.

 Capture-P (registered           Used for the detection of platelet antibodies. 
  trademark)

 Capture-R (registered           Used to detect and identify unexpected blood
  trademark)                     group antibodies.

 Capture-CMV (registered         Used for the detection of antibodies to
  trademark)                     cytomegalovirus.

 The following table includes additional products not manufactured by the
 Company but sold by the Company:

 Product Group                   Principal Use

 Microvolume Fluorimetry         Automated cell enumeration and characterization
                                 for patients undergoing transfusion therapy
                                 and HIV+ patient monitoring

 Rh (D) Immune Globulin 
  (Human)                        Administered by injection once during and once
                                 after pregnancy to an Rh negative woman who
                                 delivers an Rh positive infant to prevent
                                 hemolytic disease of the newborn.

 HLA Serums                      Transplant typing and paternity testing.

 DNA Probes                      Transplant typing, paternity testing, forensic
                                 medicine, and genetic research.

 Infectious Diseases             Diagnosis of certain infectious diseases by the
                                 methods of ELISA, Immunofluorescence and
                                 Latex Slide Tests.

 Clinical Chemistry              Blood analysis and pathological testing.


     	Solid Phase Technology.  In the Company's proprietary solid phase blood
 test system, one of the reactants (either an antigen or an antibody) is applied
 or bound to a solid support, such as a well in a microtitration plate. During
 testing, the bound reactant captures other reactants in a fluid state and binds
 those fluid reactants to the solid phase (the bound reactant). The binding
 of the fluid reactants into the solid phase occurs rapidly and results in
 clearly defined test reactions that are easier to interpret than the subjective
 results sometimes obtained from existing agglutination technology. Based on
 results obtained with Capture-P (registered trademark), Capture-R (registered
 trademark), Capture-CMV (registered trademark) and the Company's ongoing
 research, the Company believes that solid phase test results can generally be
 obtained in substantially less time than by existing techniques. 

     	In contrast, under current agglutination blood testing techniques, serum
 is mixed with red blood cells in a test tube and the technologist performs
 several procedures and then examines the mixture to determine whether there has
 been an agglutination reaction. A positive reaction will occur if the cells are
 drawn together in clumps by the presence of corresponding antibodies and
 antigens. The mixture remains in a fluid state and it is sometimes difficult
 for the technologist to determine whether the positive reaction has occurred.

     	Because of the critical importance of matching patient and donor blood,
 testing procedures using agglutination techniques are usually performed
 manually by highly educated technologists. Depending on the technical
 proficiency of the person performing the test, the process can take from 30
 minutes to one hour, and if the test results are ambiguous the entire process
 may be repeated. Thus, a significant amount of expensive labor is involved in
 such testing. Based on industry sources, the Company believes that labor costs
 are the largest component of the total cost of operating a hospital blood bank.
 The Company believes that its solid phase blood testing system improves test
 results and reduces the time necessary to perform certain blood testing
 procedures related to the transfusion of blood and blood components. 

     	Immucor has approved for sale three test systems using its solid phase
 technology: a Platelet Antibody Detection System, Capture-P (registered
 trademark); a Red Cell Antibody Detection System, Capture-R (registered
 trademark; and an Infectious Disease Test, Capture-CMV (registered trademark)
 (see below). In these three test systems, antigens are applied and bound to the
 surface of a small well in a plastic microtitration plate, and patient or donor
 serum or plasma is placed in the well. After the addition of special
 proprietary indicator cells manufactured by Immucor, positive reactions
 indicating the presence of blood group antibodies adhere to the well as a thin
 layer and negative reactions do not adhere but settle to the bottom as a small
 cell button.

     	Capture-P (registered trademark): Solid Phase Platelet Antibody Detection
 System.  A key component of plasma is platelets, small cell-like entities that
 assist in the blood clotting process. A shortage of platelets in the blood can
 significantly reduce the ability of a patient's body to control bleeding. 
 Certain multi- transfused patients, such as those on chemotherapy, often
 develop antibodies to random donor platelets. Several techniques have been
 designed by others to identify compatible platelets from random donors. Such
 techniques are time consuming and technically difficult to perform, or require
 expensive equipment, all of which limits their usefulness as routine test
 procedures. The Company believes that its solid phase platelet antibody
 detection test provides a simplified test with improved reliability over
 existing techniques and thus will be suited for routine use in transfusion
 services. The Company believes that the test provides a more accurate method
 for matching donor and recipient platelets in order to reduce the probability
 of an incompatible transfusion.  Three products are currently approved for sale
 in the Capture-P (registered trademark) system. The latest product, Capture-
 P (registered trademark) Ready-Screen (registered trademark), a solid phase
 assay for the detection of platelet IgG antibodies, incorporates Immucor's
 proprietary dried platelet technology. Previous platelet antibody detection
 tests required a source of freshly drawn platelet samples.  Capture-P
 (registered trademark) Ready-Screen (registered trademark) is supplied with
 specially selected platelets dried onto the microtitration plate wells ready
 for use. 

     	Capture-R (registered trademark): Solid Phase Red Cell Antibody Detection
 and Identification System. Unexpected blood group antibodies are found in
 patients or donors who, through pregnancy, previous transfusion or injection,
 have been exposed to foreign red blood cell antigens. Prior to blood
 transfusions all patient and donor sera is tested for the presence of these
 unexpected antibodies. In this solid phase method, reagent red blood cells
 having known blood group antigens are immobilized onto microtitration plate
 wells. Patient's or donor's serum is added to the wells.  Following incubation,
 the wells are washed to remove unbound immunoglobulins. Special indicator red
 blood cells are added and the plates are centrifuged. Positive reactions adhere
 as a thin layer while negative reactions do not adhere but settle to the bottom
 as a small cell button. Three products are currently approved for sale in the
 Capture-R (registered trademark) system. The two latest products are Capture-
 R (registered trademark) Ready-Screen (registered trademark), for the detection
 of unexpected IgG red cell antibodies, and Capture-R (registered trademark)
 Ready-ID (registered trademark), for the identification of unexpected IgG red
 cell antibodies. These two products utilize Immucor's proprietary dried red
 cell technology. Test kits include microtitration plates containing specially
 selected dried red cells supplied ready for use. This feature further reduces
 the time necessary to perform these tests with improved test results.

     	Capture-CMV (registered trademark): Solid Phase Test for Cytomegalovirus.
 CMV is a herpes virus which can be transmitted by blood and cause severe
 problems in the transfusion of newborn infants and organ transplant patients. 
 The test procedure combines patented cell drying technology with other patented
 technology to produce a test system suitable for use in large volume blood
 donor centers as well as testing the blood of individual patients. 

      Equipment.  Immucor also distributes laboratory equipment designed to
 automate certain blood test procedures and used in conjunction with the
 Company's Capture (registered trademark) products. 

      Microvolume Fluorimetry. Microvolume fluorimetry is a laser-based imaging
 system which detects fluorescently-tagged cells held in stasis in a defined
 volume, enabling an automated cellular assay delivery system.

 Products Under Development

     	Immucor continually seeks to improve its existing products and to develop
 new ones in order to enhance its market share.  Prior to their sale, any new
 products will require licensing or premarket approval by the FDA.  The Company
 employs several persons whose specific duties are to continue to improve
 existing products and develop new products for the Company's existing and
 potential customers.  The Company also has established relationships with
 other individuals and institutions who provide similar services and the Company
 expects that it will continue to do so.  The Company intends to continue its
 product development efforts primarily in the area of solid phase technology and
 in several other areas that may also be useful in connection with the
 development of additional solid phase products.  For the fiscal years ended
 May 31, 1997, 1996 and 1995, the Company spent $907,100, $997,900, and
 $1,129,600, respectively, for research and development.  See Products Under
 Development - Blood Bank Automation.  The Company may in the future acquire
 related technologies and product lines, or the companies that own them, to
 improve the Company's ability to meet the needs of its customers.

     	Blood Bank Automation.  The Company believes that the blood banking
 industry today is labor-intensive, and that a market exists for further
 automation of blood compatibility tests currently being performed manually by
 hospital and donor center blood bank technologists.

     Since 1992 the Company has worked with Bio-Tek Instruments, Inc., a wholly
 owned subsidiary of Lionheart Technologies, Inc., to combine the reagent
 manufacturing expertise of Immucor with the medical instrumentation expertise
 of Bio-Tek, to develop an automated, "walk-away", blood bank analyzer.  Bio-Tek
 has been responsible for engineering, software development and manufacturing.
 The instrument uses Immucor's proprietary Capture (registered trademark)
 reagent product technology to perform blood bank patient testing.  Known as the
 ABS2000, Immucor plans to market the instrument worldwide.  In March 1996, the
 Company filed a 510(k) application with the US Food and Drug Administration for
 market clearance. There is no assurance that the instrument will be approved
 for sale by the FDA, or that it will gain market acceptance even if approved. 
 The Company received clearance to market the instrument in Belgium, Canada,
 Italy, Sweden and the United Kingdom and has applied to other selected
 countries for export approval.

     In 1997, the Company decided to market a second automated medical
 instrument, previously referred to as the ABSHV, utilizing DYNEX Technologies,
 Inc.'s 510(k) approval for its product called the DIAS Plus.  The instrument 
 provides large blood donor centers and clinical reference laboratories
 automated batch processing and positive sample identification of routine blood
 donor tests, and uses the Company's Capture-R (registered trademark) and
 Capture-CMV (registered trademark) products.

     For the five year period ending May 31, 1997 the Company invested $4.7
 million in instrument research and development principally under research
 contracts with Bio-Tek and DYNEX. See Management's Discussion and Analysis of
 Financial Condition, Liquidity and Capital Resources.  See Regulation of
 Business.

     	Additional Solid Phase Applications.  The Company plans to continue to
 develop and refine its patented, solid phase technology.  Currently, the
 Company is developing Capture (registered trademark)-S, a solid phase screening
 test for the detection of IgG and IgM antibodies in the serum or plasma of
 blood donors with syphilis, which is pending FDA review.

     Monoclonal Antibodies.  Monoclonal antibodies are derived by fusing an
 antibody-producing cell with a tumor cell, resulting in a hybridoma cell that
 manufactures the original antibody.  The Company is actively engaged in the 
 development of additional monoclonal antibodies for a variety of uses,
 including the detection of blood group and infectious disease antigens, and for
 use in the solid phase test systems.  Monoclonal antibodies are highly
 specific, which means that their sensitivity allows them to detect and identify
 antigens with greater efficiency than other reagents.  Product quality and
 consistency is maintained from production lot to production lot.  The Company
 continues to pursue the development of such antibodies principally through its
 Canadian subsidiary, Dominion Biologicals Limited.

     	Cell Drying Technology.  Immucor has developed a proprietary method to
 modify plastic or glass surfaces to immobilize platelets and red cells. 
 Additionally, the Company has developed a proprietary method to dry platelets
 and red cells upon the modified surfaces.  This technique is currently utilized
 in several of the Company's Capture (registered trademark) products.

 Marketing and Distribution

     	Immucor's potential U.S. customers are approximately 6,000 blood banks,
 hospitals and clinical laboratories.  The Company maintains an active client
 base of over 4,000 customers worldwide, and no one customer purchases annually
 in excess of 5% of the Company's current sales volume.  The Company believes
 there is no seasonality to its sales activity and there is no material backlog
 of orders.

     	The Company has sought to increase its market share through the use of its
 experienced direct sales force and through the expansion of its product line to
 offer customers a full range of products for their reagent needs.  The Company
 believes it can increase its market share by marketing products based on its
 solid phase technology. 

     	The Company markets and sells its products to its customers directly
 through 56 sales personnel employed by the Company in the U.S., Germany,
 Portugal, Italy and Canada.  In addition, the Company utilizes 17 sales agents
 in Italy.  The Company has hired personnel whom the Company considers to be
 highly experienced and respected for their knowledge of the blood bank
 diagnostic business.  The Company believes that it can more effectively market
 its products through persons who specialize in blood testing reagents and
 related equipment, as opposed to persons who generally sell a broader line of
 medical supplies but without any expertise in blood testing products.
 Continuing technical support and service is also provided to customers through
 the Company's Consultation Laboratory, which assists the Company's customers in
 identifying certain blood group antibodies which are rare or difficult to
 detect.  Each year Immucor sponsors workshops in the U.S. and Europe to which
 customers are invited to hear the latest developments in the field.

     	The Company also markets its products internationally through distributors
 located throughout the world.  For the fiscal years ended May 31, 1997, 1996
 and 1995, the Company had foreign net sales, including net domestic export 
 sales to unaffiliated customers, of approximately $22,130,000, $18,168,000, and
 $16,187,000, respectively, and these sales accounted for approximately 62.1%,
 58.7%, and 56.0% of the Company's total net sales for the respective fiscal 
 years.  See Note 12 to the Consolidated Financial Statements.  Most of the
 Company's foreign sales occurred in Germany and in Italy where the Company
 maintains subsidiaries.  See Item 7 - Management's Discussion and Analysis 
 of Financial Condition and Results of Operations concerning the impact of
 recent changes in the management of the Company's German subsidiary.

 Suppliers

     	The Company obtains raw materials from numerous outside suppliers.  The
 Company is not dependent on any single supplier other than the joint
 manufacturers of some of the Company's monoclonal antibody-based products.  
 The  Company believes that its business relationship with suppliers is 
 excellent.

     	Certain of the Company's products are derived from blood having particular
 or rare combinations of antibodies and antigens which are found in a limited
 number of individuals.  The Company to date has not experienced any major
 difficulty in obtaining sufficient quantities of such blood for use in
 manufacturing its products, but there can be no assurance that the Company will
 always have available to it a sufficient supply of such blood.

 Regulation of Business

     	The manufacture and sale of blood banking products is a highly regulated
 business and is subject to continuing compliance with various federal and state
 statutes, rules and regulations regarding, generally, licensing, product
 testing, facilities compliance, product labeling, and consumer disclosure (see
 Industry).  The Company operates under U.S. 
 Government Establishment License No. 886 granted by the FDA in December 1982
 and under U.S. Government Establishment License No. 1151 granted by the FDA in
 May 1992 to Dominion Biologicals Limited.  An FDA license is issued for an
 indefinite period of time, subject to the FDA's right to revoke the license.
 As part of its overview responsibility, the FDA makes plant and facility
 inspections on an unannounced basis.  Further, a sample of each production lot
 of many of the Company's products must be submitted to and approved by the FDA
 prior to its sale or distribution.

     	In addition to its facilities license, the Company holds several product
 licenses to manufacture blood grouping reagents.  To obtain a product license,
 the Company must submit the product manufacturing methods to the FDA, perform a
 clinical trial of its product and demonstrate to the satisfaction of the FDA
 that the product meets certain efficacy and safety standards.  There can be no
 assurance that any future product licenses will be obtained by the Company .

     	To sell its products in Germany, Immucor GmbH must license its products
 with the Paul-Ehrlich-Institute prior to product introduction.  In addition, an
 import license for products purchased outside the European Economic Community
 is required.  To date, Immucor GmbH has been able to obtain licenses needed to
 effectively promote its products in Germany and throughout Europe.

     	Both in the U.S. and Canada, the Company has hired and retained several
 employees who are highly experienced in FDA and other regulatory authority
 compliance, and the Company believes that its manufacturing and on-going
 quality control procedures conform to the required federal and state rules and
 regulations.

 Patents, Trademarks and Royalties

     	Since 1986, the U.S. Patent Office has issued to Immucor six patents
 pertaining to its solid phase technology.

     	Immucor's solid phase technology, including patent rights, was acquired
 from five researchers at the Community Blood Center of Greater Kansas City
 pursuant to an agreement entered into on March 11, 1983, and amended in 1985
 and 1987.  In 1987, one of the researchers joined the Company as Director of
 Research and Development to continue to develop new products using the solid
 phase technology.  The agreement terminates on August 26, 2006, the date on
 which the first patent issued on the technology expires.  The Company has
 agreed to pay the researchers royalties equal to 4% of the net sales from
 products utilizing the solid phase technology.  For the fiscal years ended
 May 31, 1997, 1996 and 1995, the Company paid the researchers royalties of
 approximately $368,800, $328,400, and $278,300 under this agreement.

     	Through its development activities involving its solid phase technology,
 the Company has acquired expertise in such technology which it considers trade
 secrets. While the Company will continue to seek patent protection for its
 solid phase technology and new applications thereof, the Company believes that
 its acquired expertise and know-how, including the above mentioned trade
 secrets, will provide more important protection from competition.

     	The Company has registered the trademark "Immucor" and several product
 names, such as "ImmuAdd", "Capture", "Capture-P", "MCP", "Capture-R",
 "Ready-Screen", "Ready-ID" and "Capture-CMV".  Dominion Biologicals Limited
 has registered the trademark "NOVACLONE".

 Competition

     	There are other competitors with licenses to manufacture blood banking
 reagents in the United States.  The Company's principal U.S. competitors for
 blood bank reagents are Ortho-Clinical Diagnostics, a Johnson & Johnson
 company, and Gamma Biologicals Inc.  Additional European competitors for blood
 bank products include Biotest, a German company; and Diamed, a Swiss company. 
 All of these companies have been established longer, some have larger market
 shares than the Company, and some have substantially greater financial and
 other resources than the Company.  However, the Company believes that it is
 properly positioned to compete favorably in the business principally because of
 the quality and price of its products, the sale of innovative products such as
 the Company's Capture(registered trademark) products (see Products), continuing
 research efforts in the area of blood bank automation (see Products Under
 Development), the experience and expertise of its sales personnel (see
 Marketing and Distribution) and the expertise of its technical and customer
 support staff.

 Employees

     	At August 1, 1997, the Company had 141 full time employees in the U.S., of
 whom 28 were in sales and marketing, 91 were in manufacturing, research, and
 distribution, and 13 were in administration.  The Company has experienced a low
 turnover rate among its technical and sales staff, and none of the Company's
 employees is represented by a union.  The Company considers its employee
 relations to be good.

     	At August 1, 1997, in Germany, Portugal, Italy and Canada, the Company had
 88 full-time employees, of whom 34 were in sales and marketing, 32 were in
 distribution and administration and 22 were in manufacturing.


 Item 2.-Properties.

     	The Company leases approximately 48,000 square feet in Norcross, Georgia,
 a suburb of Atlanta, as its executive offices, laboratories and manufacturing
 facilities.  Rent charges for the fiscal year ended May 31, 1997, were
 $391,300.  The term of the lease is for a five-year period ending April 2001
 with a right to renew for an additional five years.  In Germany, the Company
 leases 1,566 square meters near Frankfurt.  Rent expense for the fiscal year
 ended May 31, 1997, totaled $209,100.  The term of the lease in Germany is
 through April 2009.  In Italy rent expense for the fiscal year ended May 31,
 1997 totaled $72,200 for 619 square meters.  The Company has three separate
 lease agreements for the facility in Italy.  The term of the first lease is
 through September 1998, the second lease is through April 2000 and the third is
 through September 2002.  In Canada, the FDA approved facility is owned by
 Company.  The Company believes all of its facilities and lease terms are
 adequate and suitable for the Company's current and anticipated business for
 the foreseeable future.

 Item 3.-Legal Proceedings.

     	The Company is not currently a party to any existing or pending legal
 proceedings. 

 Item 4.-Submission of Matters to a Vote of Security Holders. 

     	Not applicable. 
 

                                  PART II

 Item 5.-Market for Registrant's Common Equity and Related Stockholder Matters.

     	Immucor's Common Stock trades on The Nasdaq National Market System of The
 Nasdaq Stock Market under the Symbol: BLUD.  The following table sets forth the
 quarterly high and low sale prices of the Common Stock for the fiscal periods
 indicated.  These prices represent inter-dealer quotations without retail
 markups, markdowns or commissions and may not represent actual transactions.

                                   	       High             	  Low
Fiscal Year Ended May 31, 1996 
First Quarter	. . . . . . .  . . . . . 		$ 15 1/2	         	 $  8 1/2
Second Quarter	. . . . . . . . . . . . .			16               			10 1/4
Third Quarter	. . . . . . . . . . . . . . .16                   9
Fourth Quarter	. . . . . . . . . . . . . . 15 1/8		           	10 3/8

Fiscal Year Ended May 31, 1997 
First Quarter	. . . . . . . . . . . . .  $ 14             		 $  7 1/2
Second Quarter	. . . . . . . . . . . . . 	 12 3/4			            9 1/2
Third Quarter	. . . . . . . . . . . . . 		 11 1/2	    	 	       8 3/4
Fourth Quarter	. . . . . . . . . . . .. 		 10 1/2		          	  6 1/8


     	As of August 15, 1997, there were approximately 522 holders of record of
 the Company's Common Stock. The last reported sales price of the Common Stock
 on such date was $8 5/8.

     	Immucor has not declared any cash dividends with respect to its Common
 Stock. The Company presently intends to continue to retain all earnings in
 connection with its business. 

 Item 6.-Consolidated Selected Financial Data.

                (All amounts are in thousands, except per share amounts)


                                                Year Ended May 31, 

                                    1997(1)    1996     1995     1994     1993 
Statement of Income Data:
Net sales                          $35,653   $30,964  $28,892  $29,581  $30,070
Cost of sales                       15,055    12,005   10,865   12,394   11,674

Gross profit                        20,598    18,959   18,027   17,187   18,396
Operating expenses:
Selling, general, and admin.        16,714    14,367   12,575   12,179   13,302
Restructuring and other non-recurring 
charges                                  -         -        -      625        -
Research and development:
     Instrument                        342       493      644    2,005    1,245
    	General                           565       505      486      478      466

Total operating expenses            17,621    15,365   13,705   15,287   15,013

Income from operations               2,977     3,594    4,322    1,900    3,383

Other:
Other income                           819       877      677      507      556
Interest expense                      (367)     (294)    (463)    (579)    (773)
Other                                 (287)       (1)      (5)    (110)    (168)

Total other                            165       582      209     (182)    (385)

Income before income taxes           3,142     4,176    4,531    1,718    2,998
Income taxes                         1,302     1,403    1,641      992    1,165

Net income                         $ 1,840   $ 2,773  $ 2,890   $  726  $ 1,833


Income per common and
common equivalent share:           $   .22   $   .32  $   .37   $  .09  $   .25


Weighted average number of
common and common equiva-
lent shares outstanding              8,535     8,797    7,856    7,798    8,070


Balance Sheet Data:
Working capital                    $31,868   $32,524  $29,101  $21,219  $24,253
Total assets                        57,726    47,207   43,979   41,311   40,421
Long-term debt, less current 
   portion                          10,666     3,909    5,744        -    4,391
Retained earnings                   19,869    18,029   15,256   12,367   11,641
Shareholders' equity                41,221    39,345   34,067   31,026   30,389

 (1)  Includes results of Dominion Biologicals Limited since December 11, 1996.

 Item 7.-Management's Discussion and Analysis of Financial Condition and Results
   of Operations. 

      Any statements contained herein that are not historical fact are forward-
 looking statements within the meaning of the Private Securities Litigation
 Reform Act of 1995, and involve risks and uncertainties. All forward-looking 
 statements included in this document are based on information available to the
 Company on the date hereof, and the Company assumes no obligation to update any
 such forward-looking statements.  Further risks are detailed in the Company's
 filings with the Securities and Exchange Commission, including those set forth
 in this Form 10-K and Quarterly Reports on Form 10-Q.

     In July 1997 Josef Wilms, the former president of the Company's German
 subsidiary, Immucor GmbH, resigned.  Mr. Wilms is expected to remain as a
 consultant to the Company through December 31, 1997 on European sales and
 marketing matters.  Although management has reassigned Mr. Wilms' duties to
 others, given Mr. Wilms' importance in the past to the Company's operations in
 Europe, and the importance of the Company's European operations to its overall
 results, his departure could have an adverse impact on the Company's
 operations.  See Note 5 to the Consolidated Financial Statements and Item 13 -
 Certain Relationships and Related Transactions.

 (a)	Liquidity and Capital Resources

     	Net cash provided by operating activities totaled $510,000, $2,908,000,
 and $2,740,000 for the fiscal years 1997, 1996 and 1995, respectively.  As of
 May 31, 1997, the Company's cash and cash equivalents balance totaled $15.7
 million.

     	During fiscal 1997, the Company experienced an increase in trade accounts
 receivable of $1,348,000 over the previous year principally due to higher sales
 levels in the U.S. and Europe.  Other accounts receivable totaling $1,609,000
 were recorded during the fiscal year as a result of loans made to Mr. Wilms.
 See Note 5 to the Consolidated Financial Statements and Item 13 - Certain
 Relationships and Related Transactions.

     In connection with the acquisition of Dominion Biologicals Limited in
 December 1996, the Company borrowed $4,228,200 (CDN$5,741,000) under a long-
 term revolving line of credit facility with a U.S. bank maturing December 2001.
 At the same time, the Company entered into an interest rate swap agreement with
 a notional amount of $2,577,700 (CDN$3,500,000) also maturing December 2001.
 This transaction effectively converts the revolver's floating rate to a fixed
 rate on the principal balance of $2,577,700 (CDN$3,500,000).  The interest rate
 on the remaining principal of $1,650,500 (CDN$2,241,000) is adjusted every 90
 days. The balance of the acquisition of Dominion was financed from the issuance
 to Dominion's former shareholders of subordinated promissory notes totaling 
 $4,228,200 (CDN$5,741,000) due December 1999 and from the issuance of warrants
 (see Notes 3 & 4 to the Consolidated Financial Statements).

      In March 1995, the Company refinanced its remaining Deutsche Mark debt
 with the proceeds of a note payable, and entered into an interest rate swap
 agreement with a U.S. bank (see Note 4 to the Consolidated Financial
 Statements).  At May 31, 1997, the note payable with a principal amount of
 $2,348,400, and the interest rate swap agreement with a notional principal of
 the same amount, were outstanding.  During fiscal 1997 and 1996, the Company
 repaid $1,290,200 and $1,404,100, respectively.  In addition, the Company's
 German subsidiary had $72,000 in borrowings on a $0.3 million Deutsche Mark
 line of credit.

      The Company's Italian subsidiary had approximately $0.3 million in
 borrowings under an Italian lira line of credit as of May 31, 1997, with an
 additional $1.0 million available. 

     	During fiscal 1997 the Company completed the first phase of a facilities
 expansion in the U.S. which provides an additional 10,000 square feet of
 manufacturing, laboratory and office space.  Through May 31, 1997 the Company 
 spent approximately $564,000 on leasehold improvements and furnishings, and the
 Company anticipates spending an additional $650,000 in fiscal 1998 to complete
 the expansion. 

      Management believes that the Company's current cash and cash equivalents
 balance, internally generated funds, and amounts available under the lines of 
 credit are sufficient to support operations for the foreseeable future.
 Management also believes additional credit lines would be available should the
 need arise for capital improvements, acquisitions, or other corporate purposes.

 (b)	Results of Operations

 Comparison of Years Ended May 31, 1997 and May 31, 1996

     Net sales increased from $30,964,000 in fiscal 1996 to $35,654,000 in
 fiscal 1997.  Current year results include $2,085,000 in net sales from the
 operations of Dominion Biologicals Limited acquired December 1996 (see
 Liquidity and Capital Resources).  The remaining sales increase was caused by
 higher sales in both the U.S. and in the Company's European operations as a
 result of increased marketing activity.

      As a percent of sales revenue, gross profit margin declined from 61.2% to
 57.8%.  This decline was primarily due to the Company's efforts to emphasize
 longer term market share growth by focusing efforts on large national accounts
 which demand lower product pricing due to increased purchasing volume, combined
 with higher manufacturing costs which could not be passed on to customers in
 the form of higher prices given current competitive market conditions. 

      Selling, general and administrative expenses increased $2,346,900 over the
 previous year.  The acquisition of Dominion Biologicals Limited in December
 1996 contributed $512,000 of selling, general and administrative costs. Other 
 increases in selling, general and administrative expenses over the prior year
 were caused primarily by the addition of sales and marketing personnel both
 in the U.S. and in Europe, higher trade show, marketing, advertising, and 
 distribution costs, and other costs related to the Company's instrument
 programs, including the recent launch of the IMAGN (registered trademark) 2000
 (see Item 1 - Business).

     	Interest expense increased from $294,000 in fiscal 1996 to $367,000 in 
 fiscal 1997 as a result of the financing of the acquisition of Dominion 
 Biologicals Limited.  The increase was partially offset by the Company 
 reducing its outstanding principal loan balance in Germany.  See Liquidity 
 and Capital Resources.

     	The increase in other expense of $287,000 over the previous year was
 caused by currency transaction losses recorded in Europe.  An increase in the
 value of the U.S. dollar during the year required the recognition of a loss in
 the value of the U.S. dollar liabilities converted from local European
 currency.

     	As a percent of pretax income, the provision for income taxes increased in
 fiscal 1997 from 33.6% to 41.4%, principally due to the earnings of Dominion
 Biologicals Limited being subject to a higher income tax rate in Canada than
 the U.S. tax rate.  In addition, the provision increased because of the need to
 provide for income taxes on increased profits in Germany, which are also taxed
 at higher rates than income in the U.S.
	
 Comparison of Years Ended May 31, 1996 and May 31, 1995
 
      Net sales increased $2,073,000, or 7% during fiscal 1996 over fiscal 1995
 primarily due to higher export sales from the Company's U.S. facilities sold
 through distributors and increased sales in the Company's German and Italian 
 subsidiaries.  The sales growth is principally due to higher sales of the
 Company's Capture (registered trademark) products.

      While gross profit increased $933,000 with higher sales levels, as a
 percent of sales revenue, gross profit margin declined slightly.  This decline
 was primarily due to higher manufacturing costs which could not be passed on to
 customers in the form of higher prices given current competitive market 
 conditions.

     	Operating expenses increased $1,661,000 in fiscal 1996 over fiscal 1995. 
 Selling, general and administrative expenses increased $1,793,000 over the
 previous year, partially offset by a $151,000 decline in instrument research
 and development charges.  The increase was principally due to the Company's
 decision to invest heavily in selling, marketing and advertising strategies,
 which included increasing sales and marketing personnel both in the U.S. and in
 Europe, attending additional conventions and trade shows, developing additional
 journal advertising programs and other marketing costs related to the launch of
 the ABS2000.  These higher levels of spending are expected to continue as the 
 Company attempts to position itself as the industry leader in blood bank
 automation.  The Company believes current worldwide transfusion laboratory
 trends of cost containment, group purchasing and centralization of laboratory
 testing will increase the demand for automated solutions.

     	Other income for the year ended May 31, 1996 grew $200,000 over the prior
 year principally due to higher amounts of cash invested during fiscal 1996 as
 compared to last year and foreign exchange losses in the prior year period
 which did not recur in the current year.

     	As compared to the prior year, interest expense declined $168,000 in
 fiscal 1996, primarily due to the Company's decision to reduce its outstanding
 principal loan balance in Deutsche Marks.  See Liquidity and Capital Resources.

     	The provision for income taxes in fiscal 1996, as a percent of pretax
 profit, declined from 36.2% to 33.6%, when compared to the prior year. 
 Although the Company's operations in Europe generated a much higher
 contribution to pretax income in the current year compared to a year ago, no
 income tax expense was recorded in the current year, as European operations had
 sufficient net operating loss carryforwards to offset the potential tax
 liability.

 (c)	Impact of Recently Issued Accounting Standards

     	In March 1995, the FASB issued Statement No. 121, Accounting for the
 Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of,
 which requires impairment losses to be recorded on long-lived assets used in 
 operations when indicators of impairment are present and the undiscounted cash
 flows estimated to be generated by those assets are less than the assets'
 carrying amount.  Statement 121 also addresses the accounting for long-lived
 assets that are expected to be disposed of.  The Company adopted Statement 121
 in the first quarter of fiscal 1997 and the effect of adoption was not
 material.

     	In October 1995, the FASB issued Statement No. 123, Accounting for Stock-
 Based Compensation, which provides an alternative to APB Opinion No. 25,
 Accounting for Stock Issued to Employees.  However, the Company continues to
 account for stock-based compensation in accordance with APB Opinion No. 25 and
 disclose pro forma information regarding net income and earnings per share as
 required by Statement 123.

      In February 1997, the FASB issued Statement No. 128, Earning per Share,
 which is required to be adopted by the Company for the year ending May 31,
 1998.  At that time, the Company will be required to change the method
 currently used to compute earnings per share and to restate all prior periods. 
 Under the new requirements for calculating primary earnings per share, the
 dilutive effect of stock options will be excluded.  The impact is expected to
 result in an increase in primary earnings per share for the years ended May 31,
 1997 and 1996 of $.01 and $.03 per share, respectively.  The impact of
 Statement 128 on the calculation of fully diluted earnings per share is not
 expected to be material.

      In February 1997, the FASB issued Statement No. 129, Disclosure of
 Information about Capital Structure, which establishes standards for disclosing
 information about an entity's capital structure.  The Company will adopt 
 Statement 129 for the year ending May 31, 1998 and will have no impact on the
 consolidated financial statements.

 (d)	Effects of Inflation on Operations

     	Since the rate of inflation has slowed during the past few years, raw
 material prices for the Company's products have not materially increased.  The
 Company believes that any increase in personnel-related expenses or material
 costs would be experienced by others in the industry.

 Item 8.-Financial Statements and Supplementary Data.

     	The following consolidated financial statements of the Company are
          included under this item: 

 -Reports of Independent Auditors

 -Consolidated Balance Sheets, May 31, 1997, and 1996 

 -Consolidated Statements of Income for the Years Ended May 31, 1997, 1996 and
  1995

 -Consolidated Statements of Shareholders' Equity for the Years Ended May 31,
  1997, 1996 and 1995

 -Consolidated Statements of Cash Flows for the Years Ended May 31, 1997, 1996
  and 1995

 -Notes to Consolidated Financial Statements 

 -Consolidated Financial Statement Schedule




 REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS


 To the Board of Directors and Shareholders
    of Immucor, Inc.:

 We have audited the accompanying consolidated balance sheets of Immucor, Inc.
 as of May 31, 1997 and 1996 and the related consolidated statements of income,
 shareholders' equity, and cash flows for the years then ended.  Our audits 
 also included the financial statement schedule listed in the Index at Item
 14(a). These financial statements and schedule are the responsibility of the
 Company's management. Our responsibility is to express an opinion on these
 financial statements and schedule based on our audits.

 We conducted our audits in accordance with generally accepted auditing
 standards.  Those standards require that we plan and perform the audits to
 obtain reasonable assurance about whether the financial statements are free of
 material misstatement.  An audit includes examining, on a test basis, evidence
 supporting the amounts and disclosures in the financial statements.  An audit
 also includes assessing the accounting principles used and significant
 estimates made by management, as well as evaluating the overall financial
 statement presentation.  We believe that our audits provide a reasonable basis
 for our opinion.

 In our opinion, the consolidated financial statements referred to above present
 fairly, in all material respects, the consolidated financial position of
 Immucor, Inc. at May 31, 1997 and 1996, and the consolidated results of its
 operations and its cash flows for the years then ended, in conformity with
 generally accepted accounting principles. Also, in our opinion, the related
 financial statement schedule, when considered in relation to the basic
 financial statements taken as a whole, presents fairly in all material respects
 the information set forth therein.

 ERNST & YOUNG LLP

 Atlanta, Georgia
 July 16, 1997, except for the third paragraph of Note 5
      as to which the date is August 7, 1997




 REPORT OF DELOITTE & TOUCHE LLP, INDEPENDENT AUDITORS


 To the Board of Directors and Shareholders
      of Immucor, Inc.:

 We have audited the accompanying consolidated statements of income,
 shareholders' equity, and cash flows of Immucor, Inc. and subsidiaries for the
 year ended May 31, 1995.  Our audit also included the financial statement
 schedule listed in the Index at Item 14.  These financial statements and
 financial statement schedule are the responsibility of the Company's
 management.  Our responsibility is to express an opinion on the financial
 statements and financial statement schedule based on our audit.

 We conducted our audit in accordance with generally accepted auditing
 standards.  Those standards require that we plan and perform the audit to
 obtain reasonable assurance about whether the financial statements are free of
 material misstatement.  An audit includes examining, on a test basis, evidence
 supporting the amounts and disclosures in the financial statements.  An audit
 also includes assessing the accounting principles used and significant
 estimates made by management, as well as evaluating the overall financial
 statement presentation.  We believe that our audit provides a reasonable basis
 for our opinion.

 In our opinion, such consolidated financial statements present fairly, in all
 material respects, the results of operations and cash flows of Immucor, Inc. 
 and subsidiaries for the year ended May 31, 1995 in conformity with generally 
 accepted accounting principles.  Also, in our opinion, such financial statement
 schedule, when considered in relation to the basic consolidated financial
 statements taken as a whole, present fairly, in all material respects, the
 information set forth therein.


 Deloitte & Touche LLP

 Atlanta, Georgia
 July 21, 1995

IMMUCOR, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS


                                                       May 31,
ASSETS                                        1997               1996

CURRENT ASSETS:
 Cash and cash equivalents                 $15,718,234         $20,533,422
 Accounts receivable (less allowance
  for doubtful accounts of  $395,076
  in 1997 and $350,545 in 1996)             11,066,519           8,953,473
 Accounts receivable, other                  1,609,000                   -
 Inventories                                 7,662,764           5,932,923
 Income tax receivable                          38,066              37,119
 Deferred income taxes                         358,470             312,627
 Other assets                                  677,017             707,623

   Total current assets                     37,130,070          36,477,187
 
LONG-TERM INVESTMENT                         1,000,000           1,000,000

PROPERTY AND EQUIPMENT - Net                 5,333,310           3,256,524

DEFERRED INCOME TAXES                           23,176              40,128

OTHER ASSETS - Net                           1,401,164             606,866

EXCESS OF COST OVER TANGIBLE ASSETS 
 ACQUIRED - Net                             12,837,926           5,826,153


                                           $57,725,646         $47,206,858


LIABILITIES AND SHAREHOLDERS' EQUITY            

CURRENT LIABILITIES:
 Borrowings under bank line of
   credit agreements                        $    487,161        $    283,335
 Accounts payable                              3,136,117           2,656,538 
 Income taxes payable                            391,616             171,623
 Accrued salaries and wages                      695,716             594,853
 Other accrued liabilities                       551,419             246,464

   Total current liabilities                   5,262,029           3,952,813

LONG-TERM DEBT                                10,665,658           3,908,795

DEFERRED INCOME TAXES                            577,091                   -

SHAREHOLDERS' EQUITY: 
 Common stock - authorized 30,000,000 shares, 
   $.10 par value; issued and outstanding
   8,078,737 in 1997 and 8,054,380 in 1996       807,873             805,438
 Additional paid-in capital                   22,502,930          21,485,849
 Retained earnings                            19,868,924          18,029,010
 Foreign currency translation adjustment      (1,958,859)           (975,047)

   Total shareholders' equity                 41,220,868          39,345,250

                                             $57,725,646         $47,206,858

See notes to consolidated financial statements.



IMMUCOR, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME


                                              Year Ended May 31,

                                       1997          1996           1995

NET SALES                          $35,653,617   $30,964,057    $28,891,538

COST OF SALES                       15,055,254    12,004,831     10,865,349
 
GROSS PROFIT                        20,598,363    18,959,226     18,026,189

OPERATING EXPENSES:
 Selling, general and admin.        16,714,390    14,367,537     12,574,880
 Research and development:
     Instrument                        342,040       493,010        643,839 
     General                           565,101       504,902        485,799

                                    17,621,531    15,365,449     13,704,518

INCOME FROM OPERATIONS               2,976,832     3,593,777      4,321,671

OTHER:
 Other income                          819,453       877,081        677,186
 Interest expense                     (366,525)     (294,322)      (462,803)
 Other expense                        (287,556)         (250)        (5,392)

                                       165,372       582,509        208,991

INCOME BEFORE INCOME TAXES           3,142,204     4,176,286      4,530,662

INCOME TAXES                         1,302,290     1,403,651      1,640,875

NET INCOME                         $ 1,839,914   $ 2,772,635    $ 2,889,787


INCOME PER COMMON AND COMMON
 EQUIVALENT SHARE                  $       .22   $        32    $       .37


See notes to consolidated financial statements.


IMMUCOR, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
<TABLE>
                                                                            Foreign
                                              Additional                   Currency        Total
                           Common Stock         Paid-In      Retained     Translation   Shareholders'
                       Shares       Amount      Capital      Earnings     Adjustment      Equity
<S>                     <C>        <C>        <C>          <C>          <C>         <C>       
BALANCE, MAY 31, 1994   7,691,809  $ 769,181  $18,744,480  $12,366,588  $(853,850)  $ 31,026,399

Exercise of stock options  13,593      1,359       23,820                                 25,179
Foreign currency translation adjustment                                   106,559        106,559
Tax benefits related to stock options              19,090                                 19,090
Net income                                                  2,889,787                  2,889,787

BALANCE, MAY 31, 1995   7,705,402    770,540   18,787,390  15,256,375    (747,291)    34,067,014 

Exercise of stock options 349,887     34,989    2,276,993                              2,311,982
Foreign currency translation adjustment                                  (227,756)      (227,756)
Tax benefits related to stock options             440,029                                440,029
Other                        (909)      (91)      (18,563)                               (18,654)
Net income                                                 2,772,635                   2,772,635

BALANCE, MAY 31, 1996  8,054,380     805,438   21,485,849 18,029,010     (975,047)    39,345,250

Exercise of stock options 24,357       2,435     114,217                                 116,652
Foreign currency translation adjustment                                  (983,812)      (983,812)
Issuance of warrants                             800,000                                 800,000
Tax benefits related to stock options            102,864                                 102,864
Net income                                                 1,839,914                   1,839,914

BALANCE, MAY 31, 1997  8,078,737 $   807,873 $22,502,930 $19,868,924 $ (1,958,859)  $  41,220,868

See notes to consolidated financial statements.

</TABLE>

IMMUCOR, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS



                                               Year Ended May 31,

                                       1997           1996           1995

OPERATING ACTIVITIES:
 Net income                         $1,839,914     $2,772,635     $2,889,787
 Adjustments to reconcile net income
   to net cash provided by operating
   activities:
   Depreciation                      1,198,699      1,087,692        776,440
   Amortization                        449,982        328,314        299,024
   Changes in assets and liabilities:
     Accounts receivable            (1,347,699)      (943,506)    (1,028,898)
     Accounts receivable, other     (1,609,000)             -              -
     Income tax receivable             115,352         39,336         61,489
     Inventories                    (1,241,278)      (462,957)      (311,846)
     Other current assets                6,775        (96,352)      (110,739)
     Accounts payable                  343,539        231,028       (123,143)
     Income taxes payable              322,857        120,554        187,079
     Other current liabilities         430,993       (168,425)       101,073
       Total adjustments            (1,329,780)       135,684       (149,521)

Cash provided by operating
 activities                            510,134      2,908,319      2,740,266

INVESTING ACTIVITIES:
  Purchases of / deposits on
    property and equipment          (2,930,330)    (1,890,488)    (1,035,412)
  Cash paid for acquisition, 
    net of cash acquired            (4,366,734)             -              -
  (Increase) decrease in
    other assets                      (481,715)        36,729        (15,000)


Cash used in investing activities   (7,778,779)    (1,853,759)    (1,050,412)

FINANCING ACTIVITIES:
  Borrowings (repayments) under
   line of credit agreements     $    (57,367)  $     41,696  $    (307,633)
  Proceeds from issuance 
   of long term debt                4,228,163              -      5,744,238
  Repayment of notes payable       (1,300,293)    (1,404,060)    (6,921,758)
  Exercise of stock options           116,652      2,311,982         25,179
  Other                                     -        (18,654)             -


Cash provided by (used in)
  financing activities              2,987,155        930,964     (1,459,974)

EFFECT OF EXCHANGE RATE
  CHANGES ON CASH                    (533,698)      (193,783)       208,549

INCREASE/(DECREASE) IN CASH
  AND CASH EQUIVALENTS             (4,815,188)     1,791,741        438,429

CASH AND CASH EQUIVALENTS
  AT BEGINNING OF YEAR             20,533,422     18,741,681     18,303,252

CASH AND CASH EQUIVALENTS
  AT END OF YEAR                  $15,718,234    $20,533,422    $18,741,681


Noncash investing and financing 
  activities:
    Fair value of assets acquired $ 2,234,241 
    Cost in excess of assets
      acquired                      8,119,926
    Liabilities assumed              (959,270)
    Notes and warrants issued for
      assets acquired              (5,028,163)
    Net cash paid for acquisition $ 4,366,734

CASH PAID DURING THE YEAR FOR:
    Interest                     $    325,686   $    387,799   $    574,908
    Income taxes                      596,492      1,362,320      1,528,127




See notes to consolidated financial statements.
   

  

IMMUCOR, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.	NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 Nature of Business - The Company's principal business activities are the
 development, manufacturing, and marketing of immunological diagnostic medical
 products which constitute one business segment.  The Company operates
 facilities in North America and Europe.

 Consolidation Policy - The consolidated financial statements include the
 accounts of the Company and its wholly owned subsidiaries.  All significant
 intercompany balances and transactions have been eliminated in consolidation.

 Use of Estimates - The preparation of the financial statements in conformity
 with generally accepted accounting principles requires management to make
 estimates and assumptions that affect the amounts reported in the financial
 statements and accompanying notes.  Actual results could differ from those
 estimates.

 Reclassifications - Certain prior year balances have been reclassified to
 conform with the 1997 presentation.

 Concentration of Credit Risk - At May 31, 1997 approximately $13,050,649 of the
 Company's cash balance was on deposit with a high quality U.S. financial
 institution and $2,050,000 of the Company's cash balance was invested in a
 "AAA" rated security which matured June 10, 1997.  At May 31, 1996,
 substantially all of the Company's cash balances were on deposit with a high
 quality U.S. financial institution.
	
 The Company obtains raw materials from numerous outside suppliers.  The Company
 is not dependent on any single supplier other than the joint manufacturers of
 some of the Company's monoclonal antibody-based products.  The Company believes
 that its business relationship with suppliers is excellent.

 Certain of the Company's products are derived from blood having particular or
 rare combinations of antibodies and antigens which are found in a limited
 number of individuals.  The Company to date has not experienced any major
 difficulty in obtaining sufficient quantities of such blood for use in
 manufacturing its products, but there can be no assurance that the Company will
 always have available to it a sufficient supply of such blood.

 Cash and Cash Equivalents - The Company considers all highly liquid investments
 with a maturity of three months or less when purchased to be cash and cash
 equivalents.

 Inventories - Inventories are stated at the lower of first-in, first-out cost
 or market.  Cost includes material, labor, and manufacturing overhead for
 manufactured goods and material only for goods purchased for resale.

 Long-Term Investment - The long-term investment, representing a 3.4% Common
 Stock investment in Lionheart Technologies,  Inc., acquired in April 1992, is
 accounted for using the cost method of accounting (see Note 11).  Bio-Tek
 Instruments, Inc., is a wholly owned subsidiary of Lionheart Technologies, Inc.

 Property and Equipment - Property and equipment are stated at cost less
 accumulated depreciation.  Depreciation is computed using the straight-line
 method over the estimated lives of the related assets.

 Fair Value of Financial Instruments - The carrying amounts reported in the
 consolidated balance sheets for cash and cash equivalents, accounts receivable,
 long-term investment, and accounts payable approximate their fair values.  The
 fair values of the Company's long-term debt approximate the reported amounts in
 the accompanying consolidated balance sheets as their interest rates
 approximate the May 31, 1997 and 1996 market rates for similar debt
 instruments.

 Excess of Cost Over Net Tangible Assets Acquired -  Goodwill comprises the cost
 of purchased businesses in excess of values assigned to net tangible assets
 received, and is being amortized using the straight-line method over 20 to 30
 years.  The Company periodically assesses the recoverability of goodwill based
 on judgments as to the future profitability of its operations.  Accumulated
 amortization at May 31, 1997 and 1996 was $1,754,344 and $1,465,050, 
 respectively.

 Management continuously monitors and evaluates the realizability of recorded
 intangibles to determine whether their carrying values have been impaired.  In
 evaluating the value and future benefits of the intangible assets, their
 carrying value would be reduced by the excess, if any, of their carrying value
 over management's best estimate of undiscounted future cash flows over the
 remaining amortization period.  The Company believes that the carrying value of
 recorded intangibles is not impaired.

 Foreign Currency Translation - The financial statements of foreign subsidiaries
 have been translated into U.S. dollars in accordance with FASB Statement No.
 52, Foreign Currency Translation.  All balance sheet accounts have been
 translated using the exchange rates in effect at the balance sheet dates. 
 Income statement amounts have been translated using the average exchange rates
 for each year.  The gains and losses resulting from the changes in exchange
 rates from year to year have been reported separately as a component of
 shareholders' equity.  The effect of foreign currency transaction gains and
 losses has been recorded in the accompanying statements of income.

 Revenue Recognition - Revenue from the sale of the Company's reagents is
 recognized upon shipment, and revenue from the sale of the Company's medical
 instruments is recognized upon the customers' acceptance of such instruments.

 Stock Based Compensation - The Company grants stock options for a fixed number
 of shares to employees with an exercise price equal to the fair value of the
 shares at the date of grant.  The Company accounts for stock option grants in
 accordance with APB Opinion No. 25, Accounting for Stock Issued to Employees,
 and, accordingly, recognizes no compensation expense for such grants.

 Income Per Common and Common Equivalent Share - Income per common and common
 equivalent share is computed using the weighted average number of common shares
 and common share equivalents outstanding during the respective periods.  Common
 share and common share equivalents were 8,535,084 in 1997, 8,653,365 in 1996,
 and 7,808,665 in 1995.  There is no significant difference between primary and
 fully diluted per share amounts.

 Impact of Recently Issued Accounting Standards - In March 1995, the FASB issued
 Statement No. 121, Accounting for the Impairment of Long-Lived Assets and for
 Long-Lived Assets to Be Disposed of, which requires impairment losses to be
 recorded on long-lived assets used in operations when indicators of impairment
 are present and the undiscounted cash flows estimated to be generated by those
 assets are less than the assets' carrying amount.  Statement 121 also addresses
 the accounting for long-lived assets that are expected to be disposed of.  The
 Company adopted Statement 121 effective June 1, 1996, and the effect of such
 adoption was not material.

 In October 1995, the FASB issued Statement No. 123, Accounting for Stock-Based
 Compensation, which provides an alternative to APB Opinion No. 25, Accounting
 for Stock Issued to Employees.  However, the Company plans to continue to 
 account for stock-based compensation in accordance with APB Opinion No. 25 and
 disclose pro forma information regarding net income and earnings per share as
 required by Statement 123.

 In February 1997, the FASB issued Statement No. 128, Earnings per Share, which
 is required to be adopted by the Company for the year ending May 31, 1998.  At
 that time, the Company will be required to change the method currently used to
 compute earnings per share and to restate all prior periods.  Under the new
 requirements for calculating primary earnings per share, the dilutive effect of
 stock options will be excluded.  The impact is expected to result in an
 increase in primary earnings per share for the years ended May 31, 1997 and
 1996 of $.01 and $.03 per share, respectively. The impact of Statement 128 on
 the calculation of fully diluted earnings per share is not expected to be
 material.

 In February 1997, the FASB issued Statement No. 129, Disclosure of Information
 about Capital Structure, which establishes standards for disclosing information
 about an entity's capital structure.  The Company will adopt Statement 129 for
 the fiscal year ending May 31, 1998, and it will have no impact on the
 consolidated financial statements.

2.	BALANCE SHEET DETAIL
                                                           May 31,
                                                    1997            1996
Inventories:

Raw materials and supplies                       $2,278,107      $2,104,677
Work in process                                     669,112         741,723
Finished goods and goods purchased for resale     4,715,545       3,086,523

                                                 $7,662,764      $5,932,923

Property and Equipment:

Machinery and equipment                          $7,263,108      $5,183,448
Leasehold improvements                              864,772         587,732
Furniture and fixtures                              857,849         514,732

                                                  8,985,729       6,285,912
Less accumulated depreciation                    (3,652,419)     (3,029,388)

Property and equipment - net                    $ 5,333,310     $ 3,256,524


3.	PURCHASE OF DOMINION BIOLOGICALS LIMITED

	On December 11, 1996, the Company acquired all of the issued and outstanding
 common stock of Dominion Biologicals Limited for $9,256,326 (CDN$12,568,240),
 plus acquisition costs.  The acquisition was principally financed from the
 proceeds of a bank loan of $4,228,163 (CDN$5,741,000) and by the issuance of:
 (a) subordinated promissory notes totaling $4,228,163 (CDN$5,741,000), due
 three years from the closing date; and (b) warrants to purchase 478,417 and
 150,000 shares of the Company's common stock for $12.00 and $11.98,
 respectively.  The Company accounted for this transaction as a purchase 
 business combination.  The results of the operations of Dominion Biologicals
 Limited since December 11, 1996 are included in the 1997 Consolidated
 Statements of Income.

	The purchase price allocation is as follows:

 Current assets                                           $1,383,356
 Property and equipment, net                                 850,885
 Intangible asset - goodwill                               8,119,926
 Less:  Liabilities assumed                                 (959,270)

                                                          $9,394,897

	The pro forma unaudited results of operations for the years ended May 31, 1997
 and 1996, assuming consummation of the purchase as of June 1, 1995, including
 financing from the proceeds of a bank loan and issuing subordinated promissory
 notes and warrants to purchase common stock, are as follows: 


                                                    Twelve Months Ending
                                                 May 31, 1997  May 31, 1996
 Net sales                                        $37,458,262   $34,604,574
 Net income                                         1,810,411     2,664,386
 Net income per common share:
     Primary                                              .21           .31
     Fully diluted                                        .21           .30

4.	BANK CREDIT AGREEMENTS, NOTES PAYABLE, AND LONG-TERM DEBT

 The Company's Italian subsidiary has $1,696,000 in line of credit agreements
 denominated in Lira with three Italian and one Spanish bank bearing interest
 between 8.5% and 14.5%.  Outstanding borrowings were $298,396 and $283,335
 under these lines at May 31, 1997 and 1996, respectively, and were guaranteed
 by the Company.  At May 31, 1997, the Company had $1,397,600 available under
 these line of credit agreements.

 The Company's German subsidiary has a $380,274 line of credit agreement, as
 amended, denominated in Deutsche Marks with a German bank bearing interest at
 7.75%. Outstanding borrowings under this line were $72,048 at May 31, 1997.
 There were no outstanding borrowings at May 31, 1996.  At May 31, 1997, the
 Company had $308,000 available under this agreement.

 In connection with the acquisition of Dominion Biologicals Limited in December
 1996, the Company entered into a $4,566,200 (CDN$6,200,000) long-term revolving
 line of credit facility with a U.S. bank maturing December 2001 and bearing
 interest at LIBOR plus .4375%.  The Company borrowed $4,228,163 (CDN$5,741,000)
 under this line of credit facility.  At May 31, 1997, $332,400 (CDN$459,000) is
 available for future borrowings. The Company simultaneously entered into an
 interest rate swap agreement with a notional amount of $2,577,699
 (CDN$3,500,000), also maturing December 2001.  This transaction effectively
 converts the revolver's floating rate to a fixed rate of 6.6375% on the
 principal balance of $2,577,699 (CDN$3,500,000).  The interest rate on the
 remaining principal balance of $1,650,464 (CDN$2,241,000) is LIBOR plus .4375%,
 which was 3.625% at May 31, 1997, and is adjusted every 90 days.  At May 31,
 1997, the outstanding balance of the line of credit facility was $4,158,608,
 and the notional amount of the interest rate swap agreement was $2,535,313. 
 The fair value of the interest rate swap agreement (which is nominal at May 31,
 1997) is not recognized in the financial statements.  The Company also issued
 subordinated promissory notes to the former shareholders of Dominion totaling
 $4,228,163 (CDN$5,741,000), bearing interest at 6% payable semiannually with
 principal due in December 1999. 

 In March 1995, the Company refinanced its Deutsche Mark denominated debt
 through the issuance of a note payable to a U.S. bank in Deutsche Marks which
 matures September 1998 with interest of Libor plus .375%.  At the same time,
 the Company entered into an interest rate swap agreement with the bank,
 maturing September 1998, which effectively converts the note payable's floating
 rate to a fixed rate of 6.915% per annum provided the Company makes periodic
 payments.  If these payments are not made, future interest rates could vary. 
 At May 31, 1997 and 1996, the outstanding balance of the note payable was 
$2,348,382 and $3,908,795, respectively, which corresponds to the notional
 amount of the interest rate swap agreement.  The fair value of the interest
 rate swap agreement (which is nominal at May 31, 1997) is not recognized in the
 financial statements.

	The notes payable require the maintenance of certain income and other financial
 ratios, and place certain limited restrictions on the Company's ability to
 acquire other entities.

	The notes payable and interest rate swap agreements with the U.S. Bank are
 guaranteed by the Company.


5.	ACCOUNTS RECEIVABLE, OTHER

 In fiscal 1997, Mr. Josef Wilms, the former president of the Company's German
 subsidiary, Immucor GmbH, borrowed, prior to his resignation, $300,000 from the
 Company at 6% interest, secured by his warrants to purchase 143,750 shares of
 the Company's Common Stock.  At May 31, 1997,  the amount outstanding under
 this loan was $309,000 including accrued interest.

 In July 1997, management of the Company discovered that Mr. Wilms had caused
 Immucor GmbH to make unauthorized loans to him since 1994.  The amounts
 advanced were documented in the records of Immucor GmbH, including interest
 rates ranging from 7.75% to 9.5%, and were generally paid down by the end of
 each accounting period, but were not disclosed to the Company's management. 
 The largest aggregate amounts outstanding under the Immucor GmbH loans were
 $29,560 in fiscal 1994, $290,422 in fiscal 1995, $669,398 in fiscal 1996 and
 $1,310,730 in fiscal 1997.  At May 31, 1997, the aggregate outstanding amount
 under the Immucor GmbH loan was approximately $1,300,000.

 Mr. Wilms, his wife and son have granted liens on certain property owned by
 them in Germany and Portugal to collateralize the loans from the Company and
 Immucor GmbH, and Mr. Wilms has agreed to grant liens on additional property
 owned by him and located in the United States.  Management believes that the
 value of the collateral significantly exceeds the outstanding loan amounts.

 Mr. Wilms has agreed to pay all amounts borrowed from the Company and Immucor
 GmbH, plus interest at 8.25%, plus the Company's expenses in securing the
 loans, by October 31, 1997.  If these amounts are not fully repaid by that
 date, the Company intends to arrange for the sale of some or all of the
 collateral to the extent necessary to recover the unpaid balance.

 Mr. Wilms is expected to remain as a consultant to the Company through
 December 31, 1997 on European sales and marketing matters.

6.	COMMON STOCK

 At May 31, 1997, the following shares of Common Stock are reserved for future
 issuance: 	

 Common stock options - directors and employees              	1,953,643
 Common stock warrants - other	                                 933,668

                                                             	2,887,311

 In connection with the acquisition of Dominion Biologicals Limited, the Company
 issued to the sellers five and ten year warrants to acquire, in whole or in
 part, 478,417 and 150,000 shares of Immucor stock at $12.00 and $11.98 per
 share, respectively.  These warrants are exercisable one year after the
 issuance date, with the five-year warrants expiring in 2001 and the ten-year
 warrants expiring in 2006.  Immucor has agreed to register the resale of the
 shares covered by both sets of warrants upon the sellers' request after the
 exercise date or in connection with another registered public offering by the
 Company.

 In connection with prior years' business acquisitions, the Company issued to
 the sellers warrants to acquire, in whole or in part, 150,000 and 375,000
 shares of the Company's Common Stock at $26.95 and $7.75 per share, 
 respectively.  The 150,000 warrants became exercisable at the rate of 20% per
 year commencing August 1993, and expire in 2001. Through May 31, 1997, 
 219,749 of the 375,000 warrants had been exercised. The remaining 155,251
 warrants are currently exercisable and expire in 2008.

 The Company has a Shareholders' Rights Plan under which one Common Stock
 purchase right is presently attached to and trades with each outstanding share
 of the Company's Common Stock.  The rights become exercisable and transferable
 apart from the Common Stock ten days after a person or group, without the
 Company's consent, acquires beneficial ownership of, or the right to obtain
 beneficial ownership of, 20% or more of the Company's Common Stock or announces
 or commences a tender offer or exchange offer that could result in at least 20%
 ownership.  Once exercisable, each right entitles the holder to purchase one
 share of the Company's Common Stock at an exercise price of $16, subject to
 adjustment to prevent dilution.  The rights have no voting power and, until
 exercised, no dilutive effect on net income per common share.  The rights
 expire on April 20, 1999, and are redeemable at the discretion of the Board of
 Directors at $.01 each.  All reservations of shares of Common Stock for
 purposes other than the rights plan shall take precedence and be superior to
 any reservation of shares in connection with or under the rights plan.

 If a person or a group acquires at least 20% ownership, except in an offer
 approved by the Company under the rights plan, then each right not owned by the
 acquirer or related parties will entitle its holder to purchase, at the right's
 exercise price, Common Stock or Common Stock equivalents having a market value
 immediately prior to the triggering of the right of twice that exercise price.
 In addition, after an acquirer obtains at least 20% ownership, if the Company
 is involved in certain mergers, business combinations, or asset sales, each
 right not owned by the acquirer or related persons will entitle its holder to
 purchase, at the right's exercise price, shares of Common Stock of the other
 party to the transaction having a market value immediately prior to the
 triggering of the right of twice that exercise price.

7.	STOCK OPTIONS

 The Company has various stock option plans which authorize the Company's
 Compensation Committee to grant employees, officers and directors options to
 purchase shares of the Company's Common Stock.  Exercise prices of stock
 options are determined by the Compensation Committee and have been the
 estimated fair market value at the date of the grant.

 The Company's 1995 Non-Incentive Stock Option Plan authorizes the grant of
 options to employees, officers and directors for up to 1,000,000 shares of the
 Company's common stock.  All options have 10 year terms and vest and become
 fully exercisable 50% at the end of 2 years, 25% at the end of 3 years, and 25%
 at the end of 4 years of continued employment.

 The Company has elected to follow Accounting Principles Board Opinion No. 25,
 Accounting for Stock Issued to Employees, (APB 25) and related Interpretations
 in accounting for its employee stock options because the alternative fair value
 accounting provided for under FASB Statement No. 123, Accounting for Stock-
 Based Compensation, requires use of option valuation models that were not
 developed for use in valuing employee stock options.  Under APB 25, because the
 exercise price of the Company's employee stock options equals the market price
 of the underlying stock on the date of grant, no compensation is recognized.

 Pro forma information regarding net income and earnings per share is required
 by Statement 123, which also requires that the information be determined as if
 the Company has accounted for its employee stock options granted subsequent to
 June 1, 1995 under the fair value method of that Statement.  The fair value for
 these options was estimated at the date of grant using a Black-Scholes option
 pricing model with the following weighted average assumptions: a risk-free
 interest rate of 6.36% and 6.27% in fiscal 1997 and 1996, respectively, no
 dividend yields; a volatility factor of the expected market price of the
 Company's common stock of .473 based on quarterly closing prices since 1986;
 and an expected life of each option of 8 years.

 For purposes of pro forma disclosures, the estimated fair value of the options
 is amortized to expense over the options' vesting periods.  The Company's pro
 forma information follows:



                                                   1997          1996

Net income as reported                          $1,839,914    $2,772,635

Pro forma net income                            $1,738,227    $2,749,562

Pro forma earnings per share:
     Primary                                        $  .20        $  .32



 Because Statement 123 is applicable only to options granted subsequent to
 May 31, 1995, its pro forma effect will not be fully reflected until 1999.

 The Company is authorized to issue up to 1,953,643 shares of its Common Stock
 under various employee and director stock option arrangements.  These
 arrangements include employee incentive plans and various voluntary salary
 reduction plans.  Options granted under these plans become exercisable at
 various times and unless exercised expire at various dates through 2007. 
 Transactions involving these stock option arrangements are summarized as
 follows:



                                                                    Weighted
                                                 Range               Average
                                               of Exercise          Exercise
                               Shares            Prices               Price


Outstanding at May 31, 1994   1,117,741      	$.10	-	$10.00  
     Granted                    688,500      	5.38	-  	6.00
     Exercised                  (13,594)      	.10	-  	3.13
     Canceled                   (17,381)     	3.00	-  	8.125

Outstanding at May 31, 1995   1,775,266      	3.00	- 	10.00          $7.11
     Granted                     29,000      	9.00	-	 15.375         10.60
     Exercised                 (144,200)     	3.00	-  	9.33           4.98
     Canceled                   (27,719)     	3.00	-   9.33           7.63

Outstanding at May 31, 1996   1,632,347      	3.00	-  15.375          7.38 
     Granted                     36,500      	9.375	- 10.50           9.92
     Exercised                  (24,357)     	4.59	-	  6.25           4.79
     Canceled                         - 

Outstanding at May 31, 1997   1,644,490      	3.00	- 	15.375          7.53

 At May 31, 1997 and 1996, options for 1,238,240 and 918,347 shares of Common
 Stock, respectively, were exercisable, and 309,153 and 345,654 shares of Common
 Stock, respectively, were available for future grants.

 The following table as of May 31, 1997 sets forth by group of exercise price
 ranges, the number of shares, weighted average exercise prices, and weighted
 average remaining contractual lives of options outstanding, and the number and
 weighted average exercise prices of options currently exercisable.

                    Options Outstanding  Options Exercisable
                                         Weighted
    Range of        Number   Weighted    Avg.        Number   Weighted
    Exercise        of       Avg.        Contract.   of       Avg.
    Prices          Shares   Exer.Price  Life(Years) Shares   Exercise Price
$ 3.00  $ 5.50      167,978  $4.81       2.61        160,478  $4.78
  6.00    9.88    1,425,512   7.73       5.61      1,067,762   8.24
 10.00   15.38       51,000  10.86       8.35         10,000  10.00
  3.00   15.38    1,644,490   7.53       5.38      1,238,240   7.80


8.	OPERATING LEASE COMMITMENTS

 The Company leases domestic office and warehouse facilities under an operating
 lease agreement expiring in 2001 with a right to renew for an additional five
 years.  The Company leases foreign office and warehouse facilities and
 automobiles under operating lease agreements expiring at various dates through
 2009.  Total rental expense, principally for office and warehouse space, was
 $672,614 in fiscal 1997, $630,287 in fiscal 1996, and $720,040 in fiscal 1995.

 In Germany, the office facility is leased from a related party.  Rental
 payments under this lease were $209,127, $260,338, and $355,136 for fiscal
 1997, 1996, and 1995, respectively.

 The following is a schedule of approximate future annual lease payments under
 operating leases that have initial or remaining noncancelable lease terms
 in excess of one year as of May 31, 1997:

Year Ending May 31:
  1998                     	$	658,074
  1999                      		629,196
  2000                      		649,558
  2001                      		601,287
  2002                      		257,655
  Thereafter              		1,644,827

 The Company may, at its option, extend its office and warehouse facilities
 lease terms through various dates.
	
9.	INCOME TAXES

 Sources of income before income taxes are summarized below:


                                              Year Ended May 31, 
 
                                         1997        1996         1995


 Domestic Operations                   $2,122,795  $4,014,011   $4,524,194
 Foreign Operation                      1,019,409     162,275        6,468
 
   Total                               $3,142,204  $4,176,286   $4,530,662

 The provision for income taxes is summarized as follows:


                                              Year Ended May 31,
 
                                         1997         1996         1995

Current:
   Federal                             $648,258    $1,378,290    $1,536,798
   Foreign                              327,647        (8,585)          271
   State                                 50,383       112,764       163,372

                                      1,026,288     1,482,469     1,700,441

Deferred:
   Federal                              (25,849)      (70,521)      (53,295)
   Foreign                              304,892             -             -
   State                                 (3,041)       (8,297)       (6,271)

                                        276,002       (78,818)      (59,566)

Income taxes                         $1,302,290    $1,403,651    $1,640,875

 Deferred income taxes reflect the net tax effects of:  (a) temporary
 differences between the carrying amount of assets and liabilities for financial
 reporting purposes and income tax purposes; and (b) operating loss
 carryforwards.  Valuation allowances are established when necessary to reduce
 deferred tax assets to the amounts expected to be realized.  The tax effects of
 significant items comprising the Company's net deferred tax asset at May 31,
 1997 and 1996 are as follows:

                                                  Year Ended May 31, 

                                                 1997              1996
Deferred tax liabilities:
	Amortization                                $(1,568,309)      $(1,457,012)
	Depreciation                                   (199,377)                -
Deferred tax assets:
	Depreciation                                          -            63,425
	Reserves not currently deductible                69,166             8,654
	Foreign operating loss carryforwards          1,967,222         2,293,091
	Uniform capitalization                          282,608           235,771

                                                 551,310         1,143,929
Valuation allowance                             (746,755)         (791,174)

Net deferred tax asset (liability)           $  (195,445)      $   352,755


 The Company's effective tax rate differs from the federal statutory rate as
 follows:

                                                    Year Ended May 31, 

                                                  1997       1996       1995

 Federal statutory tax rate                        34%        34%        34%
 State income taxes, net of federal tax benefit     1          2          2
 Interest on state municipal obligations           (3)        (3)        (2) 
 Foreign Sales Corporation commissions             (5)         -          -
 Higher effective income tax rates of other
    countries                                       6          -          -
 Excess of cost over tangible assets acquired
    - net                                           2          -          -
 Research and development tax credits              (1)        (1)        (1)
 Other                                              7          2          3

                                                   41%        34%        36%

 As a result of utilizing compensation cost deductions arising from the exercise
 of nonqualified employee stock options for federal and state income tax
 purposes, the Company realized income tax benefits of $47,722, $384,887, and
 $19,090 in fiscal 1997, 1996, and 1995, respectively.  Additionally, the
 Company recorded income tax benefits of $55,142, both in fiscal 1997 and 1996,
 caused by patent amortization expense deductions resulting from a 1993 exercise
 of stock options previously issued in connection with the acquisition of
 certain technology (Note 10).  These income tax benefits are recognized in the 
 accompanying financial statements as additions to additional paid-in capital
 rather than as reductions of the respective income tax provisions because the
 related compensation deductions are not recognized as compensation expense for
 financial reporting purposes.

 At May 31, 1997, the Company's German subsidiary had net operating loss
 carryforwards for income tax purposes of approximately $2,230,754 which do not
 expire.  The net operating loss carryforwards result primarily due to
 differences in the timing of amortization deductions.  At May 31, 1997, the
 Company's Italian subsidiary had net operating loss carryforwards for 
 income tax purposes of approximately $1,721,741 which expire in 2000 and 2001.

10.	TECHNOLOGY RIGHTS

 In March 1983, the Company acquired rights to technology to be used in
 developing diagnostic testing products.  In connection with this acquisition, 
 the Company has agreed to pay to the inventors royalties equal to 4% of the net
 sales from products utilizing the technology.  Royalties under this agreement
 amounted to approximately $368,800, $328,400, and $278,300 in fiscal 1997,
 1996, and 1995, respectively.

11.	INSTRUMENT DEVELOPMENT AND MANUFACTURING AGREEMENTS

 The Company has contracted with Bio-Tek Instruments, Inc. (Note 1) for the
 development of a fully automated, "walk-away", blood bank analyzer.  Known as
 the ABS2000, the analyzer utilizes the Company's patented Capture(registered 
 trademark) products technology and will be marketed by the Company to hospital
 transfusion laboratories for patient testing.

 During fiscal 1996, the Company entered into a second development and
 manufacturing agreement with DYNEX Technologies, Inc.  Under the terms of the
 agreement, DYNEX will design and manufacture a second analyzer known as the 
 ABSHV utilizing the Company's Capture products technology which will be 
 marketed by the Company to blood donor centers for donor testing. 

 In fiscal 1997, 1996 and 1995, the Company incurred $342,040, $493,010 and
 $643,839, respectively, in instrument research and development principally
 under these contracts.


12.	DOMESTIC AND INTERNATIONAL OPERATIONS

 Information concerning the Company's domestic and foreign operations is
 summarized below:
		

                                      Year Ended May 31, 1997

                                U.S.       Int'l(1)      Eliminat.    Consolid.
Net Revenues: 
  Unaffiliated customers    $17,183,643   $18,469,974           -    $35,653,617

  Affiliates                  3,731,682       153,005  $(3,884,687)            -

    Total                    20,915,325    18,622,979   (3,884,687)   35,653,617

  Income from operations        860,059     2,122,972       (6,199)    2,976,832

  Identifiable assets        31,581,176    29,286,077   (3,141,607)   57,725,646



                                      Year Ended May 31, 1996

                                U.S.         Europe      Eliminat.    Consolid.
Net Revenues:
  Unaffiliated customers    $15,953,635   $15,010,422            -   $30,964,057
 
  Affiliates                  3,432,611        89,820  $(3,522,431)            -

    Total                    19,386,246    15,100,242   (3,522,431)   30,964,057

  Income from operations      2,777,277       814,871        1,629     3,593,777

  Identifiable assets        31,700,867    18,451,729   (2,945,738)   47,206,858


                                      Year Ended May 31, 1995


                                 U.S.        Europe      Eliminat.    Consolid.
Net Revenues:
  Unaffiliated customers    $15,224,035    $13,667,503           -   $28,891,538

  Affiliates                  3,292,370        145,294  (3,437,664)            -

    Total                    18,516,405     13,812,797  (3,437,664)   28,891,538

  Income from operations      3,872,959        443,142       5,570     4,321,671
 
  Identifiable assets        27,557,450     18,346,520  (1,924,728)   43,979,242

 (1)  Includes results from Canadian subsidiary:  Income from operations of
 $589,457 and Identifiable assets of $10,318,988.  
 Net revenues are not considered significant.

 Product sales to affiliates are valued at market prices.

 During the years ended May 31, 1997, 1996, and 1995, the Company had net
 domestic export sales to unaffiliated customers of approximately $3,660,000,
 $3,158,000, and $2,519,000, respectively.

14.	RETIREMENT PLAN

	The Company maintains a 401(k) retirement plan covering its domestic employees
 who meet certain age and length of service requirements, as defined.  The
 Company matches a portion of employee contributions to the plan.  During the
 years ended May 31, 1997, 1996, and 1995, the Company's matching contributions
 to the plan were $100,688, $92,700, and $84,300, respectively.  Vesting in the
 Company's matching contributions is based on years of continuous service.


15.	QUARTERLY FINANCIAL DATA (UNAUDITED)


                            (In thousands, except per share amounts)

                           Net     Gross     Operating     Net     Net Income
                          Sales    Margin     Incom      Income     Per Share 

FISCAL 1997
First Quarter            $7,957    $4,819      $831       $597        $.07
Second Quarter            8,357     4,837       695        483         .06
Third Quarter             9,640     5,706       884        344         .04
Fourth Quarter            9,700     5,236       566        416         .05

                        $35,654   $20,598    $2,976     $1,840        $.22

FISCAL 1996
First Quarter            $7,476    $4,714    $1,134       $796        $.09
Second Quarter            7,282     4,570       962        750         .09
Third Quarter             8,073     4,917       975        788         .09
Fourth Quarter            8,133     4,758       523        439         .05

                        $30,964   $18,959    $3,594     $2,773        $.32


IMMUCOR, INC. AND SUBSIDIARIES

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
YEARS ENDED MAY 31, 1995, 1996, AND 1997



                             Balance at    Charged to                 Balance 
                             Beginning     Costs and    Deductions    at End
                             of Period      Expense      (Note 1)    of Period

1995:
Allowance for doubtful accts  $178,094      $61,092      $(5,989)     $233,197

1996:
Allowance for doubtful accts  $233,197     $118,682      $(1,334)     $350,545

1997:
Allowance for doubtful accts  $350,545      $75,521     $(30,990)     $395,076


 Note 1:	"Deductions" represent accounts written off during the period less
 recoveries of accounts previously written off.

Item 9.-Changes in and Disagreements with Accountants on Accounting and 
Financial Disclosure.

	None.

PART III

Item 10.-Directors and Executive Officers of the Registrant.

	The following table sets forth certain information concerning the directors 
and executive officers of the Company. 

Name		              Age	  Position with Company

Edward L. Gallup		   58	  Chairman of the Board of Directors, President and 
                            Chief Executive Officer
Ralph A. Eatz		      53	  Director and Senior Vice President - Operations 
Richard J. Still		   48	  Director, Senior Vice President - Finance, Treasurer 
                            and Secretary
Daniel T. McKeithan		73	  Director
Didier L. Lanson		   47	  Director
Dr. Gioacchino De 
    Chirico	         44	  Director, President of Immucor Italia S.r.l.
G. Bruce Papesh		    50	  President, Dart, Papesh & Co.	

	All members of the Board of Directors hold office until the next annual 
meeting of shareholders or until their successors are duly elected and have 
qualified or until their earlier death, resignation, or removal.  All 
executive officers serve at the pleasure of the Board of Directors. 

	Messrs. Gallup, Eatz and Still founded Immucor in 1982, and have from 25 to 33
years experience in the blood banking diagnostic reagent industry.  In addition,
such officers worked together for approximately six years at Biological 
Corporation of America ("BCA"), now the blood banking reagents division of 
Biopool, Inc.  Including the time they worked together as officers of BCA and
Immucor, they now have worked together as a management team for over 22 years
in the blood banking diagnostic reagent business. 

	Edward L. Gallup has been Chairman of the Board of Directors, President and 
Chief Executive Officer of the Company since its founding.  Mr. Gallup has 
worked in the blood banking business for over 33 years. 

	Ralph A. Eatz, who has been working in the blood banking reagent field for 
over 29 years, has been a director and Vice President - Operations of the 
Company since its founding, and Senior Vice President - Operations since 
December 1988. 

	Richard J. Still has been a director of the Company since August 1982, Vice 
President - Finance (August 1982 to November 1988) and now Senior Vice 
President - Finance (since December 1988), and Secretary and Treasurer since 
February 1983.  He has worked in the blood banking reagent business for over 
25 years. 

	Daniel T. McKeithan has been a director of the Company since February 28, 1983.
Since 1986, he has served as a consultant to health care companies.  From April 
1979 until March 1986 he was employed by Blood Systems, Inc., a supplier of 
blood and blood products, as a general manager and as Executive Vice President
of Operations.  Mr. McKeithan also has 29 years experience in pharmaceutical 
and diagnostic products with Johnson and Johnson, Inc., including Vice 
President - Manufacturing of the Ortho Diagnostic Systems division. 

	Didier L. Lanson has been a director of the Company since October 24, 1989. 
Since September 1992, he has served as Vice President, Europe, of SyStemix 
International, subsidiary of SyStemix, Inc., a publicly traded biotechnology 
company recently acquired by Novartis Biotech Holding Corporation, a wholly 
owned subsidiary of Novartis Inc., and primarily engaged in the development 
of cellular processes and cellular products.  He was an Administrator and the
President and CEO of Diagnostics Transfusion ("DT"), a French corporation 
which manufactures and distributes reagent products, and President and CEO of
ESPACE VIE, a French corporation which develops and markets pharmaceutical 
blood based products and biotech products, from 1987 until December 1991.

	Dr. Gioacchino De Chirico has been President of Immucor Italia S.r.l. since 
February 1994.  From 1989 until 1994, he was employed in the United States by
Ortho Diagnostic Systems, Inc., a Johnson and Johnson Company, as General 
Manager, Immunocytometry, with worldwide responsibility.  From 1979 until 1989,
he was with Ortho Diagnostic Systems, Inc., in Italy, where he began as a 
sales representative and held several management positions, including Product
Manager and European Marketing Manager for Immunology and Infectious Disease 
products.  Immucor Italia S.r.l. was acquired by the Company on September 30,
1991.

	G. Bruce Papesh is the co-founder of Dart, Papesh & Co., a Lansing, Michigan 
based company that provides investment consulting and other financial services.
He has served as President of Dart, Papesh & Co. Inc., since 1987.  Mr. Papesh 
has over 27 years of experience in investment services while serving in stock 
broker, consulting and executive management positions.  He provides investment
services to Kenneth B. Dart and Robert C. Dart and their affiliates.  Mr. 
Papesh also serves as a Director and as Secretary of Neogen Corporation, an 
agricultural biotechnology company.

	There are no family relationships among any of the directors or executive 
officers of the Company.

	Section 16(a) Beneficial Ownership Reporting Compliance.  Section 16(a) of 
the Securities Exchange Act of 1934 and regulations of the Securities and 
Exchange Commission thereunder require the Company's executive officers and 
directors and persons who own more than ten percent of the Company's Common 
Stock, as well as certain affiliates of such persons, to file initial reports
of ownership and changes in ownership with the Securities and Exchange 
Commission and the National Association of Securities Dealers.  Executive 
officers, directors and persons owning more than ten percent of the Company's
Common Stock are required by Securities and Exchange Commission regulation to 
furnish the Company with copies of all Section 16(a) forms they file.  Based 
solely on its review of the copies of such forms received by it and written 
representations that no other reports were required for those persons, the 
Company believes that, during the fiscal year ended May 31, 1997, all filing 
requirements applicable to its executive officers, directors, and owners of 
more than ten percent of the Company's Common Stock were complied with.


Item 11.-Executive Compensation 

	The following table sets forth the compensation earned by the Company's Chief 
Executive Officer and all of the Company's other executive officers for 
services rendered in all capacities to the Company for the last three fiscal 
years.

                              SUMMARY COMPENSATION TABLE

                                                      		Long Term
                                                     		Compensation
                         	  Annual Compensation          	Awards	 
                                                Other    Securities All Other
	Name and				                                   Annual		 Underlying	Compensa-
	Principal Position Year Salary		   Bonus (1)    Comp(2) Options(3) 	tion(4)

Edward L. Gallup	   1997	 $183,993	  $	-   	     $33,415		     -		     $4,812
Chairman of the    	1996	 $176,587	  $	-   	     $31,633			    -    			$4,945
Board, President,   1995	 $170,180	  $10,000	    $28,778			  60,000	 		$4,906
and Chief Executive Officer

Ralph A. Eatz	      1997	 $178,593	  $	-	        $28,108	    		-			    $4,782
Director and Senior 1996	 $170,913	  $	-	        $26,738			    -	    		$4,975
Vice President -    1995	 $164,780	  $10,000	    $24,586			  60,000	 		$4,911
Operations

Richard J. Still	   1997	 $178,593	  $	-	         $24,639			   -			   $4,778
Director, Senior    1996	 $170,981	  $	-	         $23,058			   -			   $5,038
Vice President -    1995	 $164,780	  $10,000	     $21,816			 60,000			$4,808
Finance, Treasurer and Secretary

Josef Wilms (5)	    1997	 $193,548	  $	-	         $16,093			   -			     -
President, Immucor  1996	 $202,131	  $	-	         $17,663			   -			     -
GmbH               	1995	 $192,714	  $10,000	     $18,709			 60,000			  -

Dr. Gioacchino De 
   Chirico (6)	     1997	 $177,188	  $	-	         $13,021			   -			     -
President, Immucor  1996	 $180,073	  $	-	         $11,731			   -				    -
Italia, S.r.l. and  1995	 $163,336	  $10,000	     $11,350		  60,000				 -
Director

(1)	Represents for 1995 a bonus which was accrued for the year ended May 31, 
1995, and was paid in August 1995. 
(2)	Includes the value of life insurance premiums and an allowance for 
automobile expenditures for each of the above named executive officers as 
follows:  For 1997 - for Mr. Gallup, Eatz, Still, Wilms, and De Chirico, life 
insurance premiums of $23,815, $18,508 $15,039, $1,898 and $3,421, 
respectively, and an allowance for automobile expenditures for Mr. Gallup, 
Eatz, and Still of $9,600 each, for Mr. Wilms $14,195, and for Dr. De Chirico
$9,600.  For 1996 - for Mr. Gallup, Eatz, Still, Wilms, and De Chirico, life 
insurance premiums of $22,033, $17,138, $13,458, $2,059, and $2,131, 
respectively, and an allowance for automobile expenditures for Mr. Gallup, Eatz
and Still of $9,600 each, for Mr. Wilms $15,604, and for Dr. De Chirico 
$9,600.  For 1995 - for Mr. Gallup, Eatz, Still, Wilms, and De Chirico, life 
insurance premiums of $19,178, $14,986, $12,216, $2,009 and $1,750, 
respectively, and an allowance for automobile expenditures for Mr. Gallup, 
Eatz and Still of $9,600 each, and for Mr. Wilms $16,700 and for Dr. De Chirico
$9,600.  (3)	Represents options granted under the 1995 Stock Option Plan to 
purchase shares of the Company's Common Stock at an exercise price of $6.00.
50% of the options are exercisable beginning January 2, 1997, and 25% per 
year thereafter.
(4)  Represents amounts the Company contributed to the 401(k) retirement plan 
on behalf of the named executive officers.
(5)  Mr. Wilms resigned as President of Immucor GmbH in July 1997.
(6)	Dr. De Chirico became an executive officer and director of the Company on 
December 1, 1994.

Stock Options.

	Options Granted.  No options were granted during the fiscal year ended 
May 31, 1997.
	
Option Holdings

	The table below presents the value of unexercised options held as of the end 
of the fiscal year by each of the Company's executive officers.

                          FISCAL YEAR-END OPTION VALUES


                      Number of Securities         
                    Underlying  Unexercised       Value of Unexercised
                          Options at            In-the-Money Options at  
                         May 31, 1997             May 31, 1997 (1)
                     Exercisable	Unexercisable Exercisable	Unexercisable
Edward L. Gallup       119,250        30,000    $ 86,250    $86,250
Ralph A. Eatz          119,250        30,000      86,250     86,250
Richard J. Still       119,250        30,000      86,250     86,250
Dr. Gioacchino
     De Chirico         37,500        37,500     118,594     97,031
Josef Wilms(2)         263,000        30,000     247,969     86,250
	
(1)  	Based on the difference between the exercise price and the closing price 
for the Common Stock on 	May 31, 1997, of $8.875 as reported by NASDAQ.
(2)	Includes warrants to purchase 143,750 shares of Common Stock at an 
exercise price of $7.75, issued in connection with the acquisition of 
Immucor GmbH.  

Compensation Committee Interlocks and Insider Participation

	The Compensation Committee has responsibility for determining the types and 
amounts of executive compensation, including setting the number of stock 
options that can be granted to executive officers as a group.  Messrs. Eatz, 
McKeithan, Papesh, and Lanson are members of the Compensation Committee.  The
Stock Option Committee determines the number of shares to be granted to 
individual executive officers.  Messrs. Gallup, Eatz, and Still are members 
of the Stock Option Committee.  Ralph A. Eatz has been a director and Vice 
President - Operations of the Company since its founding, and Senior Vice 
President - Operations since December 1988 and participates in decisions on 
executive compensation.  Neither Mr. McKeithan, Mr. Papesh nor Mr. Lanson 
are, nor have they ever been, officers or employees of the Company.  Edward 
L. Gallup, Ralph A. Eatz, and Richard J. Still are the founders of the 
Company, have been directors and executive officers of the Company since its 
inception, and each of them participates in decisions on all stock options 
granted. 
	
Compensation of Directors

	Members of the Board of Directors, who are not also executive officers of the 
Company, receive $500 per meeting and are reimbursed for all travel expenses to
and from meetings of the Board.


Employment Contracts, Termination of Employment and Change of Control 
   Arrangements	

	The Company has in effect employment agreements (the "Agreements") with three 
of its executive officers: Edward L. Gallup, Ralph A. Eatz and Richard J. Still
(individually, "the Employee") entered into on January 1, 1986.  Each of the 
Agreements renews for a period of five years from each anniversary date 
unless sooner terminated.  If the Company terminates the employment of the 
Employee "without cause", the Employee would receive his base annual 
salary for the remainder of the five year period as renewed in a single lump 
sum payment upon such termination.  "Without cause" is defined in the 
Agreements to include (i) the sale, exchange, or other disposition, in one 
transaction, or in a series of related transactions, of at least 20% of the 
Company's outstanding shares of capital stock (but not including a purchase 
and sale of the Company's Common Stock by an underwriter in a public offering),
(ii) the sale of substantially all of the Company's assets to a purchaser or a 
group of associated purchasers, whether in a single transaction or a series of 
related transactions, (iii) under certain circumstances, the merger or 
consolidation of the Company, or (iv) the occurrence of any change in control
of the Company within the meaning of the federal securities law.  "Without 
cause" also includes the relocation of the Employee without the Employee's 
consent.

Immucor GmbH had in effect an employment agreement with Josef Wilms, prior to 
his resignation, effective for an indefinite period and subject to termination
by either party at the end of each calendar half year upon six months prior 
notice.  A termination by Immucor GmbH required a decision by the Company as 
its sole shareholder.  Under the terms of the employment agreement, Mr. Wilms
agreed to refrain from competition with Immucor GmbH for a period of two years 
following the termination of the agreement, and Immucor GmbH agreed to pay Mr. 
Wilms monthly installments of 1/16 of his annual compensation for such 
forbearance.  Immucor GmbH had the right to release Mr. Wilms from his 
noncompetition obligations, in which case Mr. Wilms would not have been paid.
The Company is currently discussing with Mr. Wilms matters relating to this 
agreement as a result of his resignation.  Currently, Mr. Wilms is expected 
to remain as a consultant to the Company through December 31, 1997, on 
European sales and marketing matters.  See Item 13 - Certain Relationships 
and Related Transactions.

	The Company has in effect employment agreements (the "Agreement") with Dr. 
Gioacchino De Chirico entered into on December 31, 1993.  The Agreement 
renews for a period of five years from each anniversary date unless sooner 
terminated based upon sales performance of Immucor Italia.  The Company may 
only terminate the employment agreement "for cause", as defined in the 
agreement.  If the Company terminates the employment of the Employee "without
cause", the Employee would receive his base annual salary for the remainder 
of the five year period as renewed upon such termination.  Dr. De Chirico has
agreed to refrain from competition with Immucor Italia, S.r.l. following the 
termination of the agreement for a period of two years if he is terminated 
without cause, and for a period of four years if he is terminated for cause 
or if he voluntarily terminates the agreement.

Item 12.-Security Ownership of Certain Beneficial Owners and Management. 

	The following table sets forth as of August 15, 1997, the number of shares of 
Common Stock of Immucor beneficially owned by each director of the Company, 
and by each person known to the Company to own more than 5% of the outstanding
shares of Common Stock, and by all of the executive officers and directors of 
the Company as a group. 

Name of Beneficial Owner
(and address for those 	       Shares	   Percent
owning more than five percent)	Owned(1)	of Class(1)

Edward L. Gallup            	231,357(2)	   2.8%

Ralph A. Eatz 	              307,526(2) 	  3.8%

Richard J. Still 	           159,250(2)	   1.9%

Dr. Gioacchino De Chirico	    37,500(3)		   *

Didier L. Lanson 	             8,750(4)	    *

Daniel T. McKeithan 	         53,778(4)	    *

G. Bruce Papesh                 	500(5)	    *

Kenneth B. Dart
P.O. Box 31300-SMB
Grand Cayman, 
   Cayman Islands, BWI	      472,675(6)	   5.9%

All directors and executive officers 
as a group (seven persons)	  798,661	     8.9%	
	
	* less than 1%.

(1)	Except as otherwise noted herein, percentages are determined on the basis 
of 8,078,737 shares of Common Stock issued and outstanding plus securities 
deemed outstanding pursuant to Rule 13-3(d)(1) of the Securities Exchange 
Act of 1934, as amended.  As a result, the percentage of shares of Common 
Stock is calculated assuming that the beneficial owner has exercised any 
options held by such beneficial owner that are currently exercisable, or 
exercisable within 60 days of August 15, 1997, and that no other options 
have been exercised by anyone else.  Unless otherwise indicated, the Company 
believes the beneficial owner has sole voting and investment power over such 
shares. 

(2)  Includes for each person an option to acquire 89,250 shares at an exercise
price of $9.33 and an option to acquire 30,000 shares at an exercise price of 
$6.00.

(3)	Includes a currently exercisable option to acquire 7,500 shares of Common 
Stock at an exercise price of $6.00 and an option to acquire 30,000 shares of 
Common Stock at an exercise price of $6.00.

(4)	Includes a currently exercisable option to acquire 3,750 shares at $5.40 
per share and a currently exercisable option to acquire 5,000 shares at $6.00 
per share.

(5)	Includes 400 shares over which Mr. Papesh shares investment power in his 
role as an investment advisor.

(6)	Pursuant to SEC Form 13D/A filed on December 19, 1996 (filed on 
May 15, 1997 electronically), 236,338 shares (2.93%)  were owned by 
Kenneth B. Dart, P.O. Box 31300-SMB, Grand Cayman, Cayman Islands, 
BWI, and 236,337 shares (2.93%) were owned by Robert C. Dart, c/o Dart 
Management Limited, P.O. Box 31363-SMB, Grand Cayman, Cayman Islands, BWI.  
All such shares (472,675 total, or 5.9%) are deemed under common control of 
Kenneth B. Dart as a result of an oral understanding by and between Kenneth 
B. Dart and Robert C. Dart.

Item 13.-Certain Relationships and Related Transactions. 

	The Company's German subsidiary, Immucor Mediziniche Diagnostik GmbH 
("Immucor GmbH"), leases approximately 1,566 square meters of space from the 
son of Josef Wilms, who formerly was the President of Immucor GmbH and a 
director of the Company.  Rental payments for the 1997 fiscal year totaled 
$209,127, and the lease term extends through April 2009.

	In fiscal year 1997, the Company loaned Mr. Wilms $300,000 at 6% interest, 
secured by his warrants to purchase 143,750 shares of the Company's Common 
Stock.  At May 31, 1997 and July 31, 1997, the amount outstanding under the 
loan was $309,000 and $312,000 including accrued interest.

	In July 1997, management of the Company discovered that Mr. Wilms had caused 
Immucor GmbH to make unauthorized loans to him since 1994.  The amounts advanced
were documented in the records of Immucor GmbH, including interest rates 
ranging from 7.75% to 9.5%, and were generally paid down by the end of each 
accounting period, but were not disclosed to Company's management.  The 
largest aggregate amounts outstanding were $29,560 in fiscal 1994, $290,422 
in fiscal 1995, $669,398 in fiscal 1996 and $1,310,730 in fiscal 1997.  At 
July 31, 1997, the aggregate outstanding amount payable was approximately 
$1,232,973.

	Mr. Wilms, his wife and son have granted liens on certain property owned by 
them in Germany and Portugal to collateralize the loans from the Company and 
Immucor GmbH, and Mr. Wilms has agreed to grant liens on additional property 
owned by him and located in the United States.  Management believes that the 
value of the collateral significantly exceeds the outstanding loan amounts.

	Mr. Wilms has agreed to pay all amounts borrowed from the Company and Immucor 
GmbH, plus interest at 8.25%, plus the Company's expenses in securing the 
loans, by October 31, 1997.  If these amounts are not fully repaid by that 
date, the Company intends to arrange for the sale of some or all of the 
collateral to the extent necessary to recover the unpaid balance of the 
loans at that date.

	Mr. Wilms has resigned as a director of the Company and as an employee of 
Immucor GmbH, but will remain a Managing Director of Immucor GmbH, with 
limited authority, through December 31, 1997.  Mr. Wilms is expected to 
remain as a consultant to the Company through December 31, 1997 on European 
sales and marketing matters.  If the outstanding loans are not repaid by 
October 31, 1997, Mr. Wilms will be terminated as a Managing Director of 
Immucor GmbH and a consultant to the Company.


PART IV

Item 14.-Exhibits, Financial Statement Schedules, and Reports on Form 8-K.

(a)	Documents filed as part of this report: 

1.	Consolidated Financial Statements 

The Consolidated Financial Statements, Notes thereto, and Independent Auditors' 
Reports thereon are included in Part II, Item 8 of this report. 

2.	Consolidated Financial Statement Schedule included in Part II, Item 8 of 
this report 

Schedule II - Valuation and Qualifying Accounts 

	Other financial statement schedules are omitted as they are not required or 
not applicable.

3.	Exhibits 

3.1	Articles of Incorporation (composite as of December 22, 1989) (incorporated
by reference to Exhibit 3.1 to Immucor, Inc.'s Quarterly Report on Form 10-Q 
for the fiscal quarter ended November 30, 1989). 

3.2	Bylaws (amended and restated as of August 28, 1991) (incorporated by 
reference to Exhibit 19 to Immucor, Inc.'s Quarterly Report on Form 10-Q for 
the fiscal quarter ended August 31, 1991).

4.1	Immucor, Inc. Shareholder Rights Plan, adopted April 7, 1989 (incorporated
by reference to Exhibit 4.1 to Immucor, Inc.'s Current Report on Form 8-K 
dated April 7, 1989). 

10.1	Standard Industrial Lease, dated July 21, 1982, between the Company and 
Colony Center, Ltd. (incorporated by reference to Exhibit 10.2 to Immucor, 
Inc.'s Annual Report on Form 10-K for the fiscal year ended May 31, 1985). 

10.1-1	Lease Amendment dated June 28, 1989, between the Company and Colony 
Center, Ltd. (incorporated by reference to Exhibit 10.1-1 to Immucor's Annual
Report on Form 10-K for the fiscal year ended May 31, 1989). 

10.1-2	Lease Amendment dated November 8, 1991, between the Company and Colony 
Center, Ltd. (incorporated by reference to Exhibit 10.1-1 to Immucor's Annual 
Report on Form 10-K for the fiscal year ended May 31, 1992). 

10.1-3	Lease Agreement, dated February 2, 1996, between the Company and 
Connecticut General Life Insurance Company.

10.2	Agreement, dated March 11, 1983, between the Company and The Kansas City 
Group, as amended through January 21, 1985 (incorporated by reference to 
Exhibit 10.2 to Registration Statement No. 33-16275 on Form S-1). 

10.3	Agreement dated August 27, 1987, between the Company and the Kansas City 
Group amending Exhibit 10.2 (incorporated by reference to Exhibit 10.3 to 
Immucor's Annual Report on Form 10-K for the fiscal year ended May 31, 1989). 

10.4	United States Department of Health and Human Services Establishment 
License dated December 28, 1982, for the manufacture of biological products 
(incorporated by reference to Exhibit 10.12 to Registration Statement 
No. 33-966 on Form S-1). 

10.5	United States Department of Health and Human Services Product License 
dated December 28, 1982, for the manufacture and sale of reagent red blood 
cells (incorporated by reference to Exhibit 10.13 to Registration Statement 
No. 33-966 on Form S-1). 

10.6	United States Department of Health and Human Services Product License 
dated May 20, 1983, for the manufacture and sale of blood grouping sera 
(incorporated by reference to Exhibit 10.14 to Registration Statement 
No. 33-966 on Form S-1). 

10.7	United States Department of Health and Human Services Product License 
date November 18, 1983, for the manufacture and sale of anti-human serum 
(incorporated by reference to Exhibit 10.15 to Registration Statement 
No. 33-966 on Form S-1). 

10.8*	Employment Agreement, dated January 1, 1986, between the Company and 
Edward L. Gallup (incorporated by reference to Exhibit 10.15 to Immucor, Inc.
Annual Report on Form 10-K for the fiscal year ended May 31, 1986). 

10.8-1*	Amendment to Employment Agreement dated April 7, 1989, between the 
Company and Edward L. Gallup (incorporated by reference to Exhibit 10.12-1 
to Immucor's Annual Report on Form 10-K for the fiscal year ended 
May 31, 1989). 

10.9*	Employment Agreement, dated January 1, 1986, between the Company and 
Ralph A. Eatz (incorporated by reference to Exhibit 10.16 to Immucor, Inc. 
Annual Report on Form 10-K for the fiscal year ended May 31, 1986). 

10.9-1*	Amendment to Employment Agreement dated April 7, 1989, between the 
Company and Ralph A. Eatz (incorporated by reference to Exhibit 10.13-1 to 
Immucor's Annual Report on Form 10-K for the fiscal year ended May 31, 1989). 

10.10*	Employment Agreement, dated January 1, 1986, between the Company and 
Richard J. Still (incorporated by reference to Exhibit 10.17 to Immucor, Inc. 
Annual Report on Form 10-K for the fiscal year ended May 31, 1986). 

10.10-1*	Amendment to Employment Agreement dated April 7, 1989, between the 
Company and Richard J. Still (incorporated by reference to Exhibit 10.14-1 
to Immucor's Annual Report on Form 10-K for the fiscal year ended 
May 31, 1989). 

10.11*	Employment Agreement dated September 12, 1990, between Immucor GmbH and 
Josef Wilms (incorporated by reference to Exhibit 10.11 to Immucor, Inc. 
Annual Report on Form 10-K for the fiscal year ended May 31, 1991).

10.12*	Agreement dated December 31, 1993, between Immucor Italia, S.r.l. and 
Dr. Gioacchino De Chirico (incorporated by reference to Exhibit 10.12 to 
Immucor, Inc. Annual Report on Form 10-K for the fiscal year ended 
May 31, 1995).

10.13*	Agreement dated December 31, 1993, between Immucor Italia, S.r.l. and 
Dr. Gioacchino De Chirico (incorporated by reference to Exhibit 10.13 to 
Immucor, Inc. Annual Report on Form 10-K for the fiscal year ended 
May 31, 1995).

10.14*	1995 Stock Option Plan, including form of Stock Option Agreement used 
thereunder (incorporated by reference to Exhibit 10.14 to Immucor, Inc. 
Annual Report on Form 10-K for the fiscal year ended May 31, 1995).

10.15*	1990 Stock Option Plan, including form of Stock Option Agreement used 
thereunder (incorporated by reference to Exhibit 10.15 to Immucor, Inc. 
Annual Report on Form 10-K for the fiscal year ended May 31, 1995).

10.16*	Description of 1983 and 1984 Salary Reduction Plans (incorporated by 
reference to Exhibit 10.9 to Immucor, Inc.'s Annual Report on Form 10-K for 
the fiscal year ending May 31, 1985).

10.17*	Description of 1983 Stock Option Plan (incorporated by reference to 
Exhibit 10.10 to Immucor, Inc.'s Annual Report on Form 10-K for the fiscal 
year ending May 31, 1985).

10.18*	1986 Incentive Stock Option Plan, amended July 29, 1987, including 
form of Stock Option Agreement used thereunder (incorporated by reference 
to Exhibit 10.9 to Registration Statement No. 33-16275 on Form S-1).

11.1	Statement re: computation of per share earnings. 

21	Subsidiaries of the Registrant.

23.1	Consent of Ernst & Young LLP.

23.2  Consent of Deloitte & Touche LLP.

27	Financial Data Schedule
	
    *Denotes a management contract or compensatory plan or arrangement.

(b)  Reports on Form 8-K 

The Company did not file a Current Report on Form 8-K during the quarter ended 
May 31, 1997.

(c)	Exhibits

	The exhibits required to be filed with this Annual Report on Form 10-K 
pursuant to Item 601, of Regulation S-K are listed under "Exhibits" in Part 
IV, Item 14(a)(3) of this Annual Report on Form 10-K, and are incorporated 
herein by reference.

(d)	Financial Statement Schedule
	
	The Financial Statement Schedule required to be filed with this Annual Report 
on Form 10-K is listed under "Financial Statement Schedule" in Part IV, 
Item 14(a)(2) of this Annual Report on Form 10-K, and is incorporated herein 
by reference.

SIGNATURES

	Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its 
behalf by the undersigned, thereunto duly authorized.

IMMUCOR, INC.

By:	/s/ EDWARD L. GALLUP	
	Edward L. Gallup, Chairman of the Board of Directors,
	President and Chief Executive Officer
	August 22, 1997

Pursuant to the requirements of the Securities Exchange Act of 1934, this 
report has been signed below by the following persons on behalf of the 
registrant and in the capacities and on the dates indicated. 

/s/ EDWARD L. GALLUP	
Edward L. Gallup, Director, Chairman of the Board of
Directors, President and Chief Executive Officer (Principal
Executive Officer) 
August 22, 1997

/s/ RICHARD J. STILL	
Richard J. Still, Senior Vice President-Finance, Secretary,
Treasurer, and Director (Principal Financial and
Accounting Officer) 
August 22, 1997


/s/RALPH A. EATZ	
Ralph A. Eatz, Director 
August 22, 1997


/s/DANIEL T. MCKEITHAN	
Daniel T. McKeithan, Director
August 22, 1997

/s/G. BRUCE PAPESH	
G. Bruce Papesh, Director
August 22, 1997

	
Didier L. Lanson, Director 

	
Dr. Gioacchino De Chirico, Director 



EXHIBIT INDEX

                                                                    Sequential
Number	               Description	                                 Page Number

3.1	Articles of Incorporation (composite as of December 22, 1989) (incorporated
by reference to Exhibit 3.1 to Immucor, Inc.'s Quarterly Report on Form 10-Q 
for the fiscal quarter ended November 30, 1989). 

3.2	Bylaws (amended and restated as of August 28, 1991) (incorporated by 
reference to Exhibit 19 to Immucor, Inc.'s Quarterly Report on Form 10-Q for 
the fiscal quarter ended August 31, 1991).

4.1	Immucor, Inc. Shareholder Rights Plan, adopted April 7, 1989 (incorporated
by reference to Exhibit 4.1 to Immucor, Inc.'s Current Report on Form 8-K 
dated April 7, 1989). 

10.1	Standard Industrial Lease, dated July 21, 1982, between the Company and
Colony Center, Ltd. (incorporated by reference to Exhibit 10.2 to Immucor, 
Inc.'s Annual Report on Form 10-K for the fiscal year ended May 31, 1985). 

10.1-1	Lease Amendment dated June 28, 1989, between the Company and Colony 
Center, Ltd. (incorporated by reference to Exhibit 10.1-1 to Immucor's Annual
Report on Form 10-K for the fiscal year ended May 31, 1989). 

10.1-2	Lease Amendment dated November 8, 1991, between the Company and Colony 
Center, Ltd. (incorporated by reference to Exhibit 10.1-1 to Immucor's Annual 
Report on Form 10-K for the fiscal year ended May 31, 1992). 

10.1-3	Lease Agreement, dated February 2, 1996, between the Company and 
Connecticut General Life Insurance Company.

10.2	Agreement, dated March 11, 1983, between the Company and The Kansas City 
Group, as amended through January 21, 1985 (incorporated by reference to 
Exhibit 10.2 to Registration Statement No. 33-16275 on Form S-1). 

10.3	Agreement dated August 27, 1987, between the Company and the Kansas City 
Group amending Exhibit 10.2 (incorporated by reference to Exhibit 10.3 to 
Immucor's Annual Report on Form 10-K for the fiscal year ended May 31, 1989). 

10.4	United States Department of Health and Human Services Establishment 
License dated December 28, 1982, for the manufacture of biological products 
(incorporated by reference to Exhibit 10.12 to Registration Statement 
No. 33-966 on Form S-1). 

10.5	United States Department of Health and Human Services Product License 
dated December 28, 1982, for the manufacture and sale of reagent red blood 
cells (incorporated by reference to Exhibit 10.13 to Registration Statement 
No. 33-966 on Form S-1). 

10.6	United States Department of Health and Human Services Product License 
dated May 20, 1983, for the manufacture and sale of blood grouping sera 
(incorporated by reference to Exhibit 10.14 to Registration Statement 
No. 33-966 on Form S-1). 

10.7	United States Department of Health and Human Services Product License 
date November 18, 1983, for the manufacture and sale of anti-human serum 
(incorporated by reference to Exhibit 10.15 to Registration Statement 
No. 33-966 on Form S-1). 

10.8*	Employment Agreement, dated January 1, 1986, between the Company and 
Edward L. Gallup (incorporated by reference to Exhibit 10.15 to Immucor, Inc.
Annual Report on Form 10-K for the fiscal year ended May 31, 1986). 

10.8-1*	Amendment to Employment Agreement dated April 7, 1989, between the 
Company and Edward L. Gallup (incorporated by reference to Exhibit 10.12-1 to
Immucor's Annual Report on Form 10-K for the fiscal year ended May 31, 1989). 

10.9*	Employment Agreement, dated January 1, 1986, between the Company and 
Ralph A. Eatz (incorporated by reference to Exhibit 10.16 to Immucor, Inc. 
Annual Report on Form 10-K for the fiscal year ended May 31, 1986). 

10.9-1*	Amendment to Employment Agreement dated April 7, 1989, between the 
Company and Ralph A. Eatz (incorporated by reference to Exhibit 10.13-1 to 
Immucor's Annual Report on Form 10-K for the fiscal year ended May 31, 1989). 

10.10*	Employment Agreement, dated January 1, 1986, between the Company and 
Richard J. Still (incorporated by reference to Exhibit 10.17 to Immucor, Inc.
Annual Report on Form 10-K for the fiscal year ended May 31, 1986). 

10.10-1*	Amendment to Employment Agreement dated April 7, 1989, between the 
Company and Richard J. Still (incorporated by reference to Exhibit 10.14-1 
to Immucor's Annual Report on Form 10-K for the fiscal year ended 
May 31, 1989). 

10.11*	Employment Agreement dated September 12, 1990, between Immucor GmbH and 
Josef Wilms (incorporated by reference to Exhibit 10.11 to Immucor, Inc. Annual 
Report on Form 10-K for the fiscal year ended May 31, 1991).

10.12*	Agreement dated December 31, 1993, between Immucor Italia, S.r.l. and 
Dr. Gioacchino De Chirico (incorporated by reference to Exhibit 10.12 to 
Immucor, Inc. Annual Report on Form 10-K for the fiscal year ended 
May 31, 1995).

10.13*	Agreement dated December 31, 1993, between Immucor Italia, S.r.l. and 
Dr. Gioacchino De Chirico (incorporated by reference to Exhibit 10.13 to 
Immucor, Inc. Annual Report on Form 10-K for the fiscal year ended 
May 31, 1995).

10.14*	1995 Stock Option Plan, including form of Stock Option Agreement used 
thereunder (incorporated by reference to Exhibit 10.14 to Immucor, Inc. 
Annual Report on Form 10-K for the fiscal year ended May 31, 1995).

10.15*	1990 Stock Option Plan, including form of Stock Option Agreement used 
thereunder (incorporated by reference to Exhibit 10.15 to Immucor, Inc. 
Annual Report on Form 10-K for the fiscal year ended May 31, 1995).

10.16*	Description of 1983 and 1984 Salary Reduction Plans (incorporated by 
reference to Exhibit 10.9 to Immucor, Inc.'s Annual Report on Form 10-K for 
the fiscal year ending May 31, 1985).

10.17*	Description of 1983 Stock Option Plan (incorporated by reference to 
Exhibit 10.10 to Immucor, Inc.'s Annual Report on Form 10-K for the fiscal 
year ending May 31, 1985).

10.18*	1986 Incentive Stock Option Plan, amended July 29, 1987, including 
form of Stock Option Agreement used thereunder (incorporated by reference 
to Exhibit 10.9 to Registration Statement No. 33-16275 on Form S-1).

11.1	Statement re: computation of per share earnings. 

21	  Subsidiaries of the Registrant.

23.1	Consent of Ernst & Young LLP

23.2 Consent of Deloitte & Touche LLP

27	  Financial Data Schedule

* Denotes a management contract or compensatory plan or arrangement.